PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 1A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED 
TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY
OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE
Investigational Product Number: PF-06886992
Investigational Product Name: Neisseria meningitidis Group A, B, C, W, 
and Y Vaccine (MenABCWY)
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:2019-004313-13
Protocol Number: C3511001
Phase: 3
Short Title
Phase 3 MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of 
Age 
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.
CCI
PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary of Changes and Rationale
Amendment 2 13June 2022 Protocol Sections 1.1, 3, and 9.4.1: Moved 
MenB secondary  strain immunogenicit y 
objective from Secondary Immunogenicit y 
Objectives to Tertiary /Exploratory  
Objectives.
Protocol Sections 5.2.1.1, 6.5.1, and 6.5.2: 
Made allowance for coronavirus disease 
2019 ( COVID -19) vaccinations within 
8days of stud y vaccination instead of 
14days (per the protocol administrative
change letter [ PACL ]dated 01 July  2021).
Protocol 
Section 8.1.1.2: Removal of the 
text related to secondary  strain testing .
Amendment 1 30April 2021 Protocol S ections 1.2, 1.3, 4.1, 8, 8.1.1, and 
8.10.1.4: Added an o ptional i ncrease in the 
volume of the blood draws at Visit 4 for the 
immuno genicit y
subset from 25 to 50 mL,
to support assay  development. The volume 
of blood drawn will depend on the consent
obtained.
Throughout the 
protocol: The term “CT 
SAE Report Form” has been replaced with 
“Vaccine SAE Reporting Form,” as per the 
PACL  dated 08 May  2020 .
Protocol 
Section 10.4.3, Woman of 
Childbearing Potential (WOCBP) : The 
definition of postmenopausal state has been 
amended, as per the PACL dated 
08October 2020.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 3Document History
Document Version Date Summary of Changes and Rationale
Protocol Section 4.1, Overall Design, and 
protocol summary : Administrative 
clarification:
Estimated that a n 80% /20% ratio of 
US/EU participants is a target 
relevant to the immunogenicity  
subset and the overall study ,and not 
specific to the safet y subset . 
Immunogenicit y and safety groups 
contribute to the safet y data set.
Protocol S ections 1.2, 4.1 and 9.2.1,: 
Clarification that the 
sponsor may  decide to 
proceed with less than full enrollment if an 
assessment of power shows that it is 
sufficient to meet the primary  
immunogenicit y objectives and that this 
assessment will be done in a completel y 
blinded fashion before any participants are  
unblinded or the immunogenicity  data are
accessed.
Protocol Section 10.4.1: Text updated to 
comply  with mandatory  protocol template 
text(“Must agree to use a male condom 
when engaging in an y activity  that allows 
for passage of ejaculate to another 
person.” ).
Original protocol 12 December 2019 Not applicable 
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs and any  protocol administrative 
clarification letter.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 4TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 9
1. PROTOCOL  SUMMARY ................................ ................................ ................................ ...10
1.1. Sy nopsis ..................................................................................................................10
1.2. Schema ....................................................................................................................17
1.3. Schedule of Activities (SoA) ...................................................................................18
2. INTRODUCTION ...............................................................................................................20
2.1. Study  Rationale .......................................................................................................20
2.2. Background ................................ ................................ ................................ ............. 21
2.2.1. Background of the Disease and Medical Need...........................................21
2.2.2. Prior Clinical Experience ............................................................................22
2.2.2.1. Trumenba ..................................................................................22
2.2.2.2. N imenrix (MenACWY -TT)......................................................23
2.2.2.3. Pentavalent Meningococcal Vaccine (MenABCWY)
...............23
2.3. Benefit/Risk Assessment
.........................................................................................25
3. OBJECTI VES, 
ESTIMANDS, AND ENDPO INTS ...........................................................27
4. STUDY DESIGN .................................................................................................................33
4.1. Overall Design .........................................................................................................33
4.1.1.
Approximate Duration of Participation for Each Particip ant.....................34
4.1.2. Approximate Number of Participants .........................................................34
4.2. Scientific Rationale for Study  Design .....................................................................34
4.3. Justification for Dose ..............................................................................................35
4.4. End of Study  Definition ..........................................................................................35
5. STUDY POPUL ATION
................................ ................................ ................................ ......36
5.1. I nclusion Criteria .....................................................................................................36
5.2.Exclusion Criteria ....................................................................................................37
5.2.1. Temporary  Delay  Criteria ...........................................................................38
5.2.1.1. Criteria for Temporaril y Dela ying Vaccine 
Administration ...................................................................................38
5.2.1.2. Criteria for Temporaril y Dela ying Immunogenicity  Blood 
Draw ................................ ................................ ................................ ..39
5.3. L ifesty le Considerations ..........................................................................................39
5.3.1. Contraception ..............................................................................................39

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 55.4.Screen Failures ........................................................................................................39
6. STUDY INTERVENTIO N
..................................................................................................40
6.1. Study  Intervention(s) Administered ........................................................................40
6.1.1. Administration ............................................................................................41
6.1.2. Medical Devices .........................................................................................42
6.2. Preparation/Handling/Storage/Accountability ........................................................42
6.2.1. Preparation and Dispensing ........................................................................44
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................44
6.3.1. Allocation to I nvestigational Product .........................................................44
6.3.2. Blinding of Site Personnel ..........................................................................44
6.3.3. Blinding of the Sponsor
..............................................................................45
6.3.4. Breaking the Blind ......................................................................................45
6.4. Study  Intervention Compliance ...............................................................................45
6.5. Concomitant Therapy ..............................................................................................45
6.5.1. Prohibited During the Study .......................................................................45
6.5.2. Permitted During the Study ........................................................................46
6.5.3. Prior Vaccinations and Treatments .............................................................47
6.5.4. Prohibited Prior Treatments ........................................................................47
6.6. Dose Modification ...................................................................................................47
6.7. I ntervention After the End of the Study ..................................................................47
7. DI SCONTINUATION OF S TUDY INTERVENTION AN D PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................47
7.1. Discontinuation of Study  Intervention ....................................................................47
7.2. Participant Discontinuation/Withdrawal From the Study .......................................47
7.3. L ost to Follow -
up ....................................................................................................48
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................49
8.1. Efficacy  Assessments ..............................................................................................50
8.1.1. I mmunogenicit y Assessments ....................................................................50
8.1.1.1. MenA, MenC, MenW, and MenY Serum Bactericidal 
Assay s
................................................................................................50
8.1.1.2. MenB Serum Bactericidal Assay s
.............................................50
8.1.2. Biological Samples .....................................................................................51
8.2. Safet y Assessments .................................................................................................51

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 68.2.1. Electronic Diary ..........................................................................................53
8.2.1.1. L ocal Reactions .........................................................................53
8.2.1.2. Sy stemic Events ........................................................................54
8.2.2. Pregnancy  Testing ......................................................................................55
8.3. Adverse Events and Serious Adverse Events
..........................................................55
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......56
8.3.1.1. Reporting SAEs to Pfizer Safe ty...............................................56
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
...................57
8.3.2. Method of Detecting AEs and SAEs ..........................................................57
8.3.3. Follow -up of AEs and SAEs .......................................................................57
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................57
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Expo sure ................................ ................................ ................................ .......... 58
8.3.5.1. Exposure During Pregnancy ......................................................58
8.3.5.2. Exposure During Breastfeeding ................................................58
8.3.5.3. Occupational Exposure .............................................................58
8.3.6. Medical Device Incidents (Including Malfunctions)
..................................58
8.3.6.1. Time Period for Detecting Medical Device Incidents ...............59
8.3.6.2. Follow -up of Medical Device Incidents ....................................59
8.3.6.3. Prompt Reporting of Medical Device Incidents to Sponsor .....59
8.3.6.4. Regulatory  Reporting Requirements for Medical Device 
Incidents ............................................................................................59
8.3.7. Medication Errors .......................................................................................60
8.4. Treatment of Overdose
............................................................................................61
8.5. Pharmacokinetics ....................................................................................................61
8.6. Pharmacod ynamics ................................ ................................ ................................ ..61
8.7.Genetics ...................................................................................................................61
8.8. Biomarkers ..............................................................................................................61
8.9. Health Economics ...................................................................................................61
8.10. Study  Procedures ...................................................................................................61
8.10.1. Group 1
-4 Participants -Immunogenicity Subset ................................ ....61
8.10.1.1. Visit 1 (Day  1): Vaccination 1 ................................................61

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 78.10.1.2. Visit 2 (28 to 42 Day s After Visit 1), Post –Vaccin ation 1 
Blood Draw .......................................................................................64
8.10.1.3. Visit 3 (173 to 194 Day s After Visit 1): Vaccination 2 ..........65
8.10.1.4. Visit 4 (28 to 42 Day s After Visit 3), Post –Vaccination 2 
Blood Draw .......................................................................................67
8.10.1.5. Visit 5 (168 to 196 Day s After Last Vaccination), 
Telephone Contact .............................................................................68
8.10.2. Group 5
-8 Participants -Safet y Subset .....................................................69
8.10.2.1. Visit 1 (Day  1): Vac cination 1 ................................................69
8.10.2.2. Visit 2 (28 to 42 Day s After Visit 1), Post –Vaccination 1 
Telephone Contact .............................................................................72
8.10.2.3. Visit 3 (173 to 194 Day s After Visit 1): Vaccination 2 ..........73
8.10.2.4. Visit 4 (28 to 42 Day s After Visit 3), Post –Vaccination 2 
Telephone Contact .............................................................................75
8.10.2.5. Visit 5 (168 to 196 Day s After Last Vaccination), 
Telephone Contact .............................................................................76
8.11. Unscheduled Visits ................................................................................................77
9. STATI STICAL CONSI DERATIONS
................................................................................77
9.1. Estimands and Statistical Hy potheses .....................................................................77
9.1.1. Estimands ....................................................................................................77
9.1.2. Stati stical Hy potheses .................................................................................78
9.1.3. Multiplicity  Considerations
........................................................................79
9.2. Sample Size Determination .....................................................................................79
9.2.1. I mmunogenicit y Subset (Groups 
1-4) ........................................................79
9.2.2. Additional Participants for Safet y Anal ysis (Groups 5-8)..........................83
9.3. Populations for Analysis .........................................................................................83
9.4. Statistical Analy ses
.................................................................................................84
9.4.1. I mmunogenicit y Analyses ..........................................................................85
9.4.2. Safet y Anal yses................................ ................................ .......................... 87
9.5. I nterim Anal yses.....................................................................................................88
9.5.1. Data Monitoring Committee .......................................................................88
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................89
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............89

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 810.1.1. Regulatory and Ethical Considerations ....................................................89
10.1.1.1. Reporting of Safety  Issu
es and Serious Breaches of the 
Protocol or I CH GCP .........................................................................89
10.1.2. Financial Disclosure .................................................................................90
10.1.3. I nformed Consent Process ........................................................................90
10.1.4. Data Protection .........................................................................................91
10.1.5. Dissemination of Clinical Study  Data ......................................................91
10.1.6. Data Qualit y Assurance ............................................................................92
10.1.7. Source Documents ....................................................................................94
10.1.8. Study  and Site Closure ..............................................................................94
10.1.9. Publication Policy
.....................................................................................95
10.1.10. Sponsor’s Qualified Medical Personnel .................................................95
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................96
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ......................................................................96
10.3.1. Definition of AE .......................................................................................96
10.3.2. Definition of an NDCMC .........................................................................97
10.3.3. Definition of SAE
.....................................................................................97
10.3.4. Recording/Reporting and Follow
-up of AEs and/or SAEs .......................98
10.3.5. Reporting of SAEs
..................................................................................100
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy  
Information ..............................................................................................................101
10.4.1. Male Participant Reproductive Inclusio n Criteria ..................................101
10.4.2. Female Participant Reproductive Inclusion Criteria ...............................101
10.4.3. Woman of Childbearing Potential (WOCBP) ........................................101
10.4.4. Contraception Methods ...........................................................................102
10.5. Appendix 5: L iver Safety : Suggested Actions and Follow -up Assessments ......106
10.6. Appendix 6: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow
-up, and Reporting ..................................................108
10.7. Appendix 7: Abbreviations
.................................................................................110
11.REFERENCES ................................ ................................ ................................ ................ 113

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 9LIST OF TABLES
Table 1. Study  Design ................................ ................................ ............................. 34
Table 2. Investigational Product Administration Schedule ....................................42
Table 3. Grading of Redness and Swelling .............................................................54
Table 4. Grading of Pain .........................................................................................54
Table 5. Severity  Scale for Fever ............................................................................54
Table 6. Grading of Other Sy stemic Events ...........................................................55
Table 7. Power Anal ysis for First Primary  Immunogenicity Objective 
(ACWY -
Naïve Participants).....................................................................81
Table 8. Power Anal ysis for First Primary  Immunogenicity Objective 
(ACWY -
Experienced Participants) ..........................................................81
Table 9. Power Anal ysis for Second Primary  Immunogenicity  Objective .............82
Table 10.
Probabilities of Detecting AEs at Specified Incidences ...........................83

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 101.PROTOCOL SUMMARY 
1.1.Synopsis
In Study B1971057, a first -in-human (FIH) and proof -of-concept (POC) study for 
Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY ), 543 participants 
received MenABCWY on a 0 -month and 6- month schedule.  Results from B1971057 
indicated MenABCWY is well tolerated with an acceptable safety
 profile, and also provides 
a high degree of protective immune responses among both meningococcal g roup A, C, W, 
and Y (ACWY )
-naïve and ACWY -experienced participants without interference among all 
5serogroup components.
The aim of this Phase 3 study  is to determine the immunologic noninferiority  of 
MenABCWY, an investigational pentavalent (serogroups A , B, C, W, Y) meningococcal 
vaccine, to licensed vaccines Trumenba®(serogroup B ; bivalent recombinant 
lipoprotein 2086 vaccine [bivalent rL P2086] ) and Menveo ( meningococcal groups A, C, 
Y,and W-135 oligosaccharide diphtheria conjugate vaccine [MenACWY -CRM]) by 
assessing thesafet y and immunogenicit y of MenABCWY and the comparators in healthy 
participants ≥10 to <26 years of age who have ( ACWY -experienced) and have not 
(ACWY -naïve) previously received a conjugated ACWY quadrivalent meningococcal 
vaccine .
Data obtained from prior studies supporting the licensure of the 2 vaccines comprising 
MenABCWY , meningococca l polysaccharide groups A, C, W - 135, and Y te tanus toxoid 
conjugate vaccine ( MenACWY -TT
;Nimenrix®) and Trumenba, support a favorable 
benefit -risk assessment for continued study  of MenABCWY .
Objectives, Estimands, and Endpoints
Randomization group descriptions are shown in Section 1.2.
Objectives Estimands Endpoints
Primary Immunogenicity: Primary Immunogenicity: Primary Immunogenicity:
To demonstrate that the immune 
response for N meningitidis
group A (MenA ), N meningitidis
group C (MenC ), N meningitidis
group W (MenW), and 
Nmeningitidis group Y (MenY)
induced by 2 doses of 
MenABCWY is noninferior to 
the immune response induced by 
1 dose of MenACWY- CRM in 
both ACWY- naïve and 
ACWY- experienced 
participants, sep arately.In ACWY -naïve participants receiving at 
least 1 dose (Group 2) of MenACWY -CRM 
or 2 doses (Group 1) of MenABCWY and 
who are in compliance with the key 
protocol criteria (evaluable participants):
Difference in the percentage of 
seroresponders ,defined as participants 
achieving at least a 4-fold rise inserum 
bactericidal assay using human 
complement ( hSBA )titer from baseline 
for each ACWY test strain, 1 month 
after Vaccination 2 in Group 1 
compared to 1 month after 
Vaccination 1 in Group 2.hSBA titer for each of the 
ACWY test strains.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 11Objectives Estimands Endpoints
For participants with a baseline 
hSBA titer below  the limit of 
detection (LOD ;or an hSBA titer 
of 1:4), a 4 -fold response is 
defined as a nhSBA titer of ≥1:16.
For participants with a baseline 
hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and lower limit of 
quantitation ( LLOQ )(ie, hSBA
titer of 1:8), a 4 -fold response is 
defined as a nhSBA titer of 
≥4times LLOQ.   
For participants with a baseline 
hSBA titer of ≥LLOQ, a 4 -fold 
response is defined as a nhSBA 
titer of ≥4 times the baseline titer.
In ACWY -experienced participants 
receivin g at least 1 dose (Group 4) of 
MenACWY -CRM or 2 doses (Group 3) of 
MenABCWY and who are in compliance 
with the key protocol criteria (evaluable 
participants):
Difference in the percentage of 
seroresponders ,defined as participants 
achieving at least a 4-fold rise in hSBA 
titer from baseline for each ACWY test 
strain, 1 month after Vaccination 2 in 
Group 3 compared to 1 month after 
Vaccination 1 in Group 4.  
For participants with a baseline 
hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold 
response is defined as a nhSBA 
titer of ≥1:16.
For participants with a baseline 
hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and LLOQ 
(ie,hSBA titer of 1:8), a 4 -fold 
response is defined as a nhSBA 
titer of ≥4 times LLOQ.
For participants with a baseline
hSBA titer of ≥LLOQ, a 4 -fold 
response is defined as a nhSBA 
titer of ≥4 times the baseline titer.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 12Objectives Estimands Endpoints
To demonstrate that the immune 
response induced by 2 doses of 
MenABCWY is noninferior to 
the immune response induced by 
2 doses of Trumenba.In participants receiving at least 2 doses of 
investigational product and who are in 
compliance with the key protocol criteria 
(evaluable participants):
Differences in the percentage of
participants achieving an hSBA 
titer ≥ LLOQ (1:16 for strain A22 and 
1:8 for strains A56, B24, and B44) for all 
4 primary MenB test strains combined 
(composite response), in Groups 1 and 3 
combined compared to Groups 2 and 4 
combined, at 1 month after 
Vaccination 2. 
Difference in the percentage of 
participants achieving at least a 4-fold 
risein hSBA titer from baseline for each
of the 4 primary MenB test strains, in 
Groups 1 and 3 combined compared to 
Groups 2 and 4 combined, at 1 month 
after Vaccination 2.
For participants with a baseline 
hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold 
response is defined as an hS BA titer 
of ≥1:16.
For participants with a baseline 
hSBA titer of ≥LOD (ie, hSBA titer 
of ≥1:4) and LLOQ, a 4 -fold 
response is defined as an hSBA titer 
of ≥4 times the LLOQ.
For participants with a baseline 
hSBA titer of ≥LLOQ , a 4-fold 
response is defined as an hSBA titer 
of ≥4 times the baseline titer.hSBA titer for each of the 
primary MenB test strains 
(A22, A56, B24 ,and 
B44).
Primary Safety: Primary Safety: Primary Safety:
To describe the safety profile of 
MenABCWY, as measured by 
local reactions, systemic events, 
adverse events (AEs), serious 
adverse events (SAEs), newly 
diagnosed chronic medical 
conditions (NDCMC s), 
medically attended AEs (MAEs), 
andimmediate AEs.In participants receiving at least 1 dose of 
investigational product, expressed in 
MenABCWY groups (Groups 1, 3, 5 ,and 7 
combined) and Trumenba groups 
(Groups 2, 4, 6 ,and 8 combined) :
The percentage of participants reporting 
local reactions, systemic eve nts, and use 
of antipyretic medication within 7 days 
after each vaccination .Local reactions (pain, 
redness, and 
swelling).
Systemic events 
(fever, vomiting, 
diarrhea, headache, 
fatigue, chills, muscle 
pain other than 
muscle pain at a ny 
injection site, and 
joint pain). 
Use of antipyretic 
medication .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 13Objectives Estimands Endpoints
The percentage of participants reporting 
at least 1 SAE, at least 1 MAE ,and at 
least 1 NDCMC during the follow ing 
time periods:
o30 Days after each vaccination.
o30 Days after any vaccination.
oDuring the vaccination phase 
(from the first study vaccination 
[Visit 1] through 1 month after the 
second study vaccination 
[Visit 4]).
oDuring the follow -up phase 
(from 1 month after the second 
study vaccination [Visit 4] 
through 6 months af ter the second 
study vaccination [Visit 5]).
oThroughout the study (from the 
first study vaccination [Visit 1] 
through 6 months after the second 
study vaccination [Visit 5]).
The percentage of participants reporting 
at least 1 AE during the following time 
periods:
o30 Days after each vaccination.
o30 Days after any vaccination.
oDuring the vaccination phase 
(from the first study vaccination 
[Visit 1] through 1 month after the 
second study vaccination 
[Visit 4]).
The percentage of participants reporting 
at leas t 1 immediate AE.
The percentage of participants who 
missed days of school or w ork because 
ofAEs.AEs, SAEs, MAEs, 
NDCMCs, and 
immediate AEs .
Days missing from 
school or w ork 
because of AEs.
Secondary 
Immunogenicity:Secondary 
Immunogenicity:Secondary 
Immunogenicity:
To demonstrate that the immune 
response for MenA, MenC, 
MenW, and MenY induced by 
1dose of MenABCWY is 
noninferior to the immune 
response induced by 1 dose of 
MenACWY -CRM , in both 
ACWY- naïve and 
ACWY- experienced 
participants, sep arately.In ACWY -naïve participants receiving at 
least 1 dose of investigational product and 
who are in compliance with the key 
protocol criteria (evaluable participants):
Difference in the percentage of 
seroresponders ,defined as participants 
achieving at least a 4-fold risein hSBA 
titer from baseline for each ACWY test 
strain, 1 month after Vaccination 1 in 
Group 1 compared to Group 2.hSBA titer for each of the 
ACWY test strains.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 14Objectives Estimands Endpoints
For participants with a baseline 
hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold 
response is defined as a nhSBA 
titer of ≥1:16.
For participants with a baseline 
hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and LLOQ (ie, 
hSBA titer of 1:8), a 4 -fold 
response is defined as a nhSBA 
titer of ≥4 times LLOQ.
For participants with a baseline 
hSBA titer of ≥LLOQ, a 4 -fold 
response is defined as a nhSBA 
titer of ≥4 times the baseline titer.
In ACWY -experienced participants 
receiving at least 1 dose of investigational 
product and w ho are in compliance with the 
key protocol criteria (evaluable 
participants):
Difference in the percentage of 
seroresponders ,defined as participants 
achieving at least a 4-fold rise in hSBA 
titer from baseline for each ACWY test 
strain, 1 month after Vaccination 1 in 
Group 3 compared to Group 4.  
For participants with a baseline 
hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold 
response is defined as a nhSBA 
titer of ≥1:16.
For participants with a baseline 
hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and LLOQ 
(ie,hSBA titer of 1:8), a 4 -fold 
response is defined as a nhSBA 
titer of ≥4 times LLOQ.
For participants with a baseline 
hSBA titer of ≥LLOQ, a 4 -fold 
response is defined as a nhSBA 
titer of ≥4 times the baseline titer.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 15Overall Design
This is a Phase 3, randomized, active -controlled, observer -blinded multicenter trial in 
which approximately  2413 participants ≥10 to <26 y ears of age will be randomly  assigned 
toreceive either MenABCWY and saline, or Trumenba and MenACWY- CRM ,as 
shown inSection 1.2.  The study  will include evaluation of both ACWY -naïve and 
ACWY -experienced individuals.  All participants will be na ïve to an
y meningococcal group 
B vaccine prior to enrollment.
Participants in Groups 1 through 4 will be considered an immunogenicity  subset, and will 
contribute to both the safety  and immunogenicity  anal yses; these participants will have blood 
drawn prior to Vaccination 1 and 1 month afte r Vaccinations 1 and 2.  Participants in 
Groups 5through 8 will be considered a safet y subset and will contribute to the safet y 
analysis onl y, and will not have blood drawn for immunogenicit y evaluations.
Randomization will be stratified b y prior vaccinat ion history .  Overall , a pproximately  
1225 ACWY -naïve and 1188 ACWY -experienced participants (having received 1 dose of 
Menactra or Menveo ≥4 years prior to the date of randomization) will be enrolled.  Of the se
total participants, up to 675 ACWY -naïve and 1013 ACWY -experienced participants will 
contribute to the immunogenicity  subset.
Participants enrolled in the immunogenicity subset will contri bute to both immunogenicit y 
and safe ty evaluations. Additionally , participants will be enrolled inasafety  subset that will 
contribute exclusively  to the 
safet y evaluation. Numbers enrolled inthe safety  subset will 
therefor e be based on numbers needed to achieve anoverall number of enrolled participants ,
all of whom will contribute to the safet y eval uation. Numbers stated in the protocol to be 
enrolled b y group across immunogenicit y and safety subsets ( Section 1.2 andTable 1)are 
estimates only . 
Additionally ,
randomization will be stratified by  geographic region.  The overall participant 
distribution by  region will be approximately  80% from the US and approximately  20% from 
other regions. Among the participants in the immunogenicity subset, approximately  80% 
will be enrolled in US investigative sites, and approxi
mately 20% will be enrolled in other 
regions.  
Regional or safety /immunogenicity  group enrollment shifts may be necessary  based 
on the availability  of participants with specific characteristics (age group or ACWY 
experience) in a given location based on local im munization practices. However ,these 
minor shifts from the ori ginall y targeted numbers will not deviate from original targets to a 
degree that will impact the overall stud y design or endpoint assessments of the study .
Enrollment targets will also be adjusted to achieve appropriate representation by  age group 
(participants 10 to <18 years old and participants 18 to <26 y ears old) within each subset, and 
ACWY strata within each subset. 
Approximately  2413 participants wi ll be enrolled, and each participant will participate in the 
study  for approximately  12 months.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 16Statistical Methods
The first primary  objective is designed to assess if the immune response induced by  2 doses 
of MenABCWY is noninferior to the immune respons e induced b y 1 dose of 
MenACWY -CRM, for ACWY -naïve and for ACWY -experienced participants separately. 
This will be assessed as the difference in the percentage of seroresponders, defined as 
participants achieving at least a 4 -fold rise in hSBA titer from b aseline for each ACWY test 
strain, 1 month after Vaccination 2 in Groups 1 and 3 separately  (MenABCWY groups) 
compared to 1 month after Vaccination 1 in Groups 2 and 4 separatel y (MenACWY -CRM 
groups) using a noninferiority  criterion of -10%. The first sec ondary  immunogenicity  
objective is also designed to assess the noninferiority  in MenA, MenC, MenW, and MenY 
responses in the MenABWCY groups compared to the MenACWY -CRM groups, using the 
same criteri on; this comparison will be made 1 month after Vaccinatio n 1 in Groups 1 and 3 
separately  (MenABCWY groups) compared to Groups 2 and 4 separatel y (MenACWY -CRM 
groups).
The second primary  objective is designed to assess if the immune response for MenB 
induced b y 2 doses of MenABCWY is noninferior to the immune re sponse induced by  
2 doses of Trumenba. This will be assessed using:
1.the differences in the percentage of participants achieving an hSBA titer ≥ LLOQ 
(1:16 for 
strain A22 and 1:8 for strains A56, B24, and B44) for all 4 primary  MenB test 
strains combined (composite response), in the MenABCWY groups compared to the 
Trumenba groups , at 1 month after Vaccination 2, and 
2.the difference in the percentage of participants achieving at least a 4-fold rise in hSBA
titer from baseline for each of the 4 primary  MenB test strains, in the 
MenABCWY 
groups compared to the Trumenba groups , 1 month after Vaccination 2, using a 
noninferiority  criterion of -10%. The second primary  objective will be met if the 
noninferiority criteri onis met for all these MenB endpoints.
The primary  safet y objective will be assessed b y descriptive summaries of local reactions, 
systemic events, use of antipy retic medication, AEs, SAE s, NDCMC s, MAEs, and 
immediate AEs in the MenABCWY and Trumenba groups as described in Section 9.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 171.2.Schema
Vaccination 1 Follow -up
Visit 1aVaccination 2 Follow -up
Visit 2aTelephone 
Contact
Approximate 
Month0 1 6 7 12
Visit Number 1 2 3 4 5
ACWY-naïve 
participantsGroup 1 (n=450) MenABCWY +
salineMenABCWY
Group 2 (n=225) Trumenba +
MenACWY -CRMTrumenba
ACWY-
experienced 
participantsGroup 3  (n=675) MenABCWY +
salineMenABCWY
Group 4 (n=338) Trumenba +
MenACWY -CRMTrumenba
Blood draw
(Groups 1 -4 only)25mL 25mL 25mLor 
50 mL
ACWY-naïve 
participantsGroup 5 (n=500) MenABCWY +
salineMenABCWY
Group 6
(n=50)Trumenba +
MenACWY -CRMTrumenba
ACWY-
experienced 
participantsGroup 7 (n=125) MenABCWY +
salineMenABCWY
Group 8
(n=50)Trumenba +
MenACWY -CRMTrumenba
a.Follow -up Visits 1 and 2 w ill be telephone contacts for safety -assessment -only participants in 
Groups 5through 8, for whom blood samples will not be obtained.
A portion of the projected number of participant enrollment slots may be moved from the 
safet y subset to the immunogenicity subset to achieve appropriate regional distribution for 
the overall stud y population and the immunogenicity subset .  This determination will be 
made b y the sponsor while still blinded
.The sponsor may  decide to proceed with less than 
full enrol lment if an assessment of power shows that it is sufficient to meet the primary  
objectives.  This assessment will be done in a c ompletely  blinded fashion before any  
participants are unblinded or the immunogenicit y data areaccessed.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 181.3.Schedule of Activi ties (SoA)
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduc t evaluations or 
assessments required to protect the well -being of the participant. 
Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Visit Description Vaccination 1 Follow -up 
Visit 1aVaccination 2 Follow -up 
Visit 2aTelephone Contact
Approxim ate Month 0 1 6 7 6 Months After Last 
Study Vaccination
Visit Window Day 1 28 to 42 Days 
After Visit 1173 to 194 Days 
After Visit 128 to 42 Days 
After Visit 3168 to 196 Days After 
Last Vaccination
Informed consent X
Revie w eligibility criteria X
Dem ography X
Confirm continued eligibilitybX X X
Medical history and physical examination X
Record previous PRP -OMP vaccinations X
Record any previous meningococcal vaccinations X
Urine pregnancy test for female participants 
(obtain results prior to vaccination)X X
Oral temperature (prior to vaccination) X X
Randomization X
Obtain blood sample for participants in the 
immunogenicity s ubset (Groups 1 -4 only) prior to 
vaccination25 mL 25 mL 25 mL
(or 50 mLc)
Investigational product administration and observationdX X
Record nonstudy vaccinations X X X

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2 , 13June 2022
PFIZER CO NFIDENTIAL
Page 19Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Visit Description Vaccination 1 Follow -up 
Visit 1aVaccination 2 Follow -up 
Visit 2aTelephone Contact
Approxim ate Month 0 1 6 7 6 Months After Last 
Study Vaccination
Visit Window Day 1 28 to 42 Days 
After Visit 1173 to 194 Days 
After Visit 128 to 42 Days 
After Visit 3168 to 196 Days After 
Last Vaccination
Provide participant with an e -diary, caliper, measuring 
tape/ruler, and digital therm ometer, if necessary ,and 
provide instructions on useX X
Revie w and collect e -diary X X
Assess reactogenicity and record use of antipyretic 
medicationseDays1 to 7 Days1 to 7
Provide the participant w ith a contact card X
Provide the participant w ith a memory aid X
Com plete Study Visit/Telephone Contact AE 
ChecklistfX X X X
Record concomitant medications used to treat AEs X X X X X
(S)AE collection appropriate for the visitgX X X X X
Abbreviations: e -diary = electronic diary; PRP -OMP = polyribosylribitol phosphate oligosaccharide of Haemophilus influenzae type b conjugated to outer 
membrane protein.
a.Follow -up Visits 1 and 2 w ill be telephone contacts for safety -assessment -only participants in Groups 5 through 8, for whom blood samples will not be 
obtained.
b.Ensure that the participant continues to be eligible for the study, and continues to comply with contraception requirements, as appropriate.
c.In the subset of participants ≥16 years of age .
d.Observe the participant for at least 30 minutes (or longer as per local practice) after the investigational product administration for any acute reactions.
e.Betw een visits, review the e -diary  data online at frequent intervals.  Contact the parent(s)/legal guardian or the participant in order to obtain stop dates for 
any local reactions, sys temic events, or use of antipyretic medication that were ongoing on the last day that the e -diary was completed.
f.Checklist includes questions regarding newly diagnosed chronic medical conditions, medically attended adverse events, and mis sed days of sch ool or 
work, as well as about neuroinflammatory and autoimmune conditions, such as transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
g.Please refer to Section 8.3.1 of the protocol .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 202.INTRODUCTION
Bivalent rLP2086 (120 µg) and MenACWY-TT (5 µg of each of the 4 meningococcal 
polysaccharides A, C, W -135, and Y conjugated to 44 µg of tetanus toxoid) are available 
commerciall y as Trumenba®and Nimenrix®, respectivel y.  
Pfizer intends to develop a pentavalent meningococcal vaccine (MenABCWY) by  combining 
bivalent rL P2086 (supplied as a 0.7 -mL prefilled sy ringe
[PFS]) and MenACWY -TT.  The 
target indication for the candidate pentavalent vaccine is active immunization to prevent 
invasive disease caused by Nmeningitidis groups A, B, C, W, and Y in individuals 
10through 25 years of age , regardless of prior exposure to a conjugated ACWY quadrivalent 
meningococcal vaccine .
Trumenba is composed of 2 recombinant lipidated factor H binding protein ( fHBP ) variants 
from MenB, one from fHBP subfamily  A and one from subfamily  B (A05 and B01, 
respectivel y), and is indicat ed for active immunization to prevent invasive disease caused by  
MenB .  Trumenba is approved for use in individuals 10 through 25 y ears of age in the 
United States and individuals 10 y ears of age and older in Europe and other locations.
Nimenrix is compose d of capsular pol ysaccharides from each of the A, C, W, and Y groups 
of Nmeningitidis conjugated to tetanus toxoid, and is indicated for active immunization of 
individuals 6 weeks of age and older against invasive meningococcal diseases caused b y 
Nmeningitidis group sA, C, W -135, and Y and is approved in Europe and other locations. 
2.1.Study Rationale
In Study B1971057, a nFIH and POC study  for MenABCWY, 543 participants received 
MenABCWY on a 0- month and 6 -month schedule.  Results from B1971057 indicated 
MenABCWY is well tolerated with an acceptable safet y profile, and also provides a high 
degree of protective immune responses among both ACWY -naïve and ACWY -experienced 
participants without interference among all 5 serogroup components.
The aim of this Phase 3 study  is to determine the immunologic noninferiority  of 
MenABCWY to licensed vaccines Trumenba and MenACWY -CRM (Menveo) b y assessing 
the safet y and immunogenicity  of MenABCWY and the comparators in both ACWY -naïve 
and ACWY -experienc ed healthy  participa nts ≥10 to <26 y ears of age.
Data obtained from prior studies supporting the licensure of the 2 vaccines comprising 
MenABCWY, Nimenrix and Trumenba ,support a favorable benefit -risk assessment for 
continued study  of MenABCWY.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 212.2.Background
2.2.1. Background of the Disease and Medical Need
Nmeningitidis is an obligate human pathogen that colonizes the upper respiratory  tract ,
which , in some individuals, can cause serious, life- threatening invasive meningococcal 
disease (IMD ), which clinically  presents as septicemia, meningitis, or both.1  N meningitidis
serogroups A, B, C, W, and Y are 5 of the 6 meningococcal serogroups that cause the vast 
majority  of meningococcal disease globall y
,2and disease incidence is highest in infants and 
children younger than 5 years of age, adolescents and young adults (16 to 21 years) ,and 
older adults ( ≥65 y ears).3  In the United States, meningococcal disease is primarily  caused b y 
groups B, C, W, and Y, which are responsible for approximately  79% of disease across all 
ages.4
Current prevent ive vaccination strategies generally  require separate immunizations at 
different times for an ACWY conjugate vaccine as well as a separate serogroup B vaccine.  
In the United States, 
MenACWY vaccination rates among adolescents 13 to 17 y ears of age 
are est imated to be 86.6% for ≥1 dose and 50.8% for ≥2 doses ,and MenB vaccination 
coverage among 17 -year-olds approach esonly 17.2%.5  In the U nited States and Europe, 
MenB has become the most common cause of IMD over the past several years. In the 
United States, MenB now exceeds all other serogroups in incidence, accounting for 85% of 
IMD among individuals 11 to 23 y ears of age, with C, W ,and Y accounting for the 
remainder despite high vaccination rates in targeted adolescents.4,6  These data support the 
idea that all 5 serogroups contribute to disease in adolescents and young adults and that a 
multivalent vaccine incorporating serogroup B would have significant public health utili ty.
Temporal variations in IMD incidence occur naturally .  In industrialized countries, disease 
rates range from 0.1 cases per 100,000 individuals during endemic periods to 5 to 15 or more 
cases per 100,000 individuals during prolonged epidemics
.7,8,9,10  During 2017, the incidence 
of IMD in the U nited States in young adolescents (11 to 15 y ears) was 0.04 while at the same 
time much higher, 0.2, in 16
-to 23 -year-olds.4  Although the overall incidence of endemic 
IMD is quite low, it can rise significantl y during epidemics, particularl y on US college 
campuses, where it has been as high as high as 21.1 to 134 p er 100,000 in 
data reported in 
2014.11,12
In the United States, the Center
sfor Disease Control and Prevention’s Advisory  Committee 
on Immunization Practices ( ACIP)recommends that children 11 to 12 y ears of age should 
receive a MenACWY conjugate vaccination with a booster dose at 16 y earsof age and that 
adolescents and young adults 16 to 23 years of age may  be vaccinated with a MenB vaccine 
to provide short -term protection against most strains of serogroup B meningococcal disease.  
Given that meningococcal serogroups B, C, W ,and Y cause disease in the United States 
through earl y adolescence and young adulthood, with unacceptable mortality  and morbidity  
outcomes with an increasing contribution of serogroup B to IMD in this age group, a safe and 
effective pentavalent vaccine, which is currentl y not available, would fulfill an unmet need 
for broad protection against I MD that is more durable in the setting of the disease’s changing 
epidemiology .13

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 222.2.2. Prior Clinical Experience
2.2.2.1. Trumenba
Trumenba was approved on 29 October 2014, under 21 Code of Federal Regulations (CFR) 
601 Subpart E -Accelerated Approval of Biological Products for Serious or L ife-Threatening 
Illnesses, for active immunization of individuals 10 through 25 years of age to prevent 
invasive disease caused by meningococcal group B.
Trumenba was subsequently  approved in the European Union ( EU) on 24 May  2017 for 
active immunization of individuals 10 y ears of age and older to prevent IMD caused b y
MenB . Trumenba has received marketing authorization in 45 countries and is currentl y 
marketed in 22 countries.   
Approval of Trumenba was based on the demonstration of safet y and a serological correlate 
that showed in Phase 2 studies the induction of serum bactericidal activity  against 
4serogroup B strains that are representative of prevalent US strains.  These were measured 
using hSBAs.  As a requirement of licensure, Phase 3 studies were conducted to confirm the 
safet y and immune responses ass ociated with the 3 -dose schedule.  As of 28 April 2019, it is 
estimated that 23,586 participants have participated in the Trumenba clinical development 
program: 12,027 participants were exposed to Trumenba alone; a total of 5202 participants 
received Trume nba in combination with: diphtheria, tetanus, and acellular pertussis and
Haemophilus influenzae type b vaccine (DTa P-Hib); hepatitis B virus andinactivated 
poliomy elitis virus vaccine (HBV -IPV)/Prevenar®(32); diphtheria, tetanus, and acellular 
pertussis andinactivated poliomy elitis virus vaccine (DTaP-IPV)(372); human 
papillomavirus vaccine (HPV4 )(992); quadrivalent meningococcal pol ysaccharide conjugate 
and diphtheria, tetanus, and acellular pertussis vaccine ( MCV4- Tdap ) (884); 
MenACWY -CRM (1057); o r saline (1865); 543 participants received bivalent rL P2086 
mixed with MenACWY -TT (Nimenrix) as a single injection in S tudy B1971057; and 
5847 participants received control. The estimated cumulative worldwide unit distribution 
forTrumenba from launch thr ough 28 April 2019 is approximately 3,367,496 doses.
Alicensure persistence -of-immunity  and booster study , B1971033, show edthat persistence 
of immunity  after the 2-and 3 -dose primary  Trumenba series schedules utilized in 
Studies B1971010 and B1971012 follows similar patterns over 4 years, declining by  
Year1
and remaining stable through Year 4, regardless of the primary  series schedule.  The immune 
responses following a booster dose with Trumenba 4 y ears after the primary  Trumenba series 
resulted in g enerally  higher hSBA titers compared to 1 month after the primary  series, 
irrespective of whether participants received a 2- dose or 3- dose series, demonstrating a 
robust anamnestic response.  Protective hSBA titers (hSBA ≥ LLOQ) also persisted in a high 
proportion of booster recipients ( 57.5% to 82.8%, depending on the test strain) for up 2 y ears 
after the booster dose. 

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 232.2.2.2. Nimenrix (MenACWY -TT)
Nimenrix was first licensed for use in the EU on 20 April 2012 for the active immunization 
of individuals from the a ge of 12 months and above against IMD caused by N meningitidis
serogroups A, C, W -135, and Y. On 12 December 2016, the indication of Nimenrix was 
extended in Europe to infants 6 weeks of age and older . Nimenrix has received marketing 
authorization in 83 countries and is currently  marketed in 59 countries.
Nimenrix is not presently  licensed in the United States, though there is an open 
investigational new drug application (IND) (BB- IND 13278).  Licensure outside of the 
United States was based on safet y and demonstration of immunologic noninferiorit y 
(based mainl y on comparing proportions of participants with serum bactericidal assay  
using rabbit complement [ rSBA] titers of at least 1:8) to licensed meningococcal vaccines. 
Cumulatively , it is estimated that 21,520 participants have participated in the Nimenrix 
clinical development program (CDP ). Worldwide distribution for Nimenrix from launch 
through 19 April 2019 is approximately  16,124,606 doses.
The immunogenicit y studies conducted in participants from 12 months of age and above 
demonstrate that 1 dose of MenACWY- TT induces a response that is similar to or higher 
than the response induced by  licensed meningococcal vaccines used as control, and that the 
vaccine is able to induce immunologic memory  against the 4 meningococcal serogroups in 
individuals vaccinated as toddlers 12 to 14 months of age, historicall y an age group that is 
not responsive to meningococcal polysaccharide vaccines.  Follow -up studies demonstrate 
that persistence of the responses elicit ed by the vaccine is similar toor higher than 
persistence of those elicited by  the licensed meningococcal poly saccharide vaccines 
Meningitec®and Mencevax®when assessed using the GlaxoSmithKline (GSK )rSBA.  
2.2.2.3. Pentavalent Meningococcal Vaccine (MenABCWY)
MenABCWY is an investigational pentavalent meningococcal vaccine consisting of bivalent 
rLP2086 (supplied as a 0.7 -mL PFS) and MenACWY -TT, which are administered as a single 
injection after reconstituting the MenACWY- TT components with the bivalent rL P2086
suspension.  MenABCWY has been administered to 543 individuals participating in 
Study B1971057. 
Results from B1971057 demonstrated the immunogenicity  and safety  of MenABCWY in 
adolescents and young adults. This was a randomized, active- controlled, obser ver-blinded 
multicenter trial in which approximately  1600 participants ≥10 to <26 y ears of age were 
randomly  assigned to receive either MenABCWY (n=543) on a 0 -month and 6 -month 
schedule, or Trumenba on a 0 -month and 6- month schedule and MenACWY - CRM (n=105 7) 
at the same time as the first dose of Trumenba. All participants were naïve to any  
meningococcal group B vaccine prior to enrollment and approximately  half were naïve to 
prior MenACWY vaccination , while the other half were considered ACWY-experienced, 
having had no more than 1 previous ACWY component vaccine at least 4 years prior to 
enrollment. Stage 1, which included the vaccination phase of the primary  series, is now 
complete. 

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 24Immunogenicit y noninferiority  evaluations of hSBA responses to the MenAC WY component 
of MenABCWY showed that MenABCWY, both after 1 and 2 doses, was noninferior to a 
single dose of MenACWY- CRM by  3 different statistical methods for individuals who 
were either ACWY- naïve or ACWY -experienced. One and 2doses of MenABCWY 
were noninferior to 1 dose of MenACWY -CRM at the 10% margin. Specifically , for 
ACWY -naïve 
participants, the percentage -of-responder ( ≥4-fold rise) differences between 
asingle dose of 
MenABCWY compared to a single dose of MenACWY -CRM were 1.1% 
(-2.1, 3.7) for serogroup A, 5.5% ( -1.3, 11.9) for serogroup C, 10.7% (4.9, 16.1) for 
serogroup W,and 14.1% (8.1, 19.7) for serogroup Y. Among ACWY -experienced 
participants, the percentage differences were -0.8% ( -4.5, 2.1) for serogroup A, -2.4% 
(-6.4, 0.9) for C, -0.8% ( -4.5, 2.0) for W, and - 0.3% ( -4.6, 3.3) for Y. Similarly , 
noninferiority  was also established for ≥4 -fold rise in the percentage of responders after 
2doses of MenABCWY compared to a single dose of MenACWY -CRM for ACWY -naïve 
and ACWY -experienced participants.
Among the ACWY -naïve participants, percent age-of-responder differences were 1.1% 
(-2.2, 3.8) for serogroup A, 26.5% (21.6, 31.1) for C, 21.5% (17.1, 25.8) for W, and 22.9% 
(17.7, 27.6) for Y. Among the ACWY -experienced participants, differences were - 0.8% 
(-4.7, 2.1) for serogroup A, - 0.9% ( -4.9, 2.2) for C, -1.9% ( -6.1, 1.2) for W, and -1.6% 
(-6.5, 2.3) for Y. However, GMTs were markedl y higher among ACWY -experienced 
participants than ACWY-naïve participants after MenABCWY administration, indicating the 
pentavalent vaccine’s booster effect for ACWY components. Therefore, MenABCWY, 
whether given as a single dose, or as a 2 -dose series separated b y 6months, was noninferior 
to a single dose of MenACWY -CRM, regardless of prior ACWY experience .
For the MenB component of MenABCWY, hSBA responses after the second dose were 
noninferior to those for Trumenba. Noninferiorit y was established at the 10% margin for 
percent ageofresponders who achieved ≥4 -fold rise in hSBA titer over baseline among 
MenABCWY recipients compared to Trumenba recipients for the 4 primary test strains :A22, 
A56, B24 ,and B44.
Reactogenicit y data were collected for 7 day s following each vaccination by electronic 
diaries (e -diaries )applying the s ame methodology  used in the Trumenba development 
program.  Local and s ystemic reactogenicity was similar between MenABCWY and 
Trumenba/MenACWY -CRM recipients, with injection site pain (93.4% vs 91.1%) being the 
most common local reaction after an y vaccination, followed b y swelling (26.0% vs 22.4%) 
and redness (24.5% vs 21.1%). No significant differences among MenABCWY recipients 
who were considered either ACWY -naïve or ACWY -experienced were observed. 

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 25During the vaccination phase (from the first vaccination through 1 month after the second 
vaccination) ,similar proportions of participants receiving MenABCWY reported any  
AE(39.2%) compared to Trumenba + MenACWY- CRM recipients (40.7%) ,and the 
2groups were also similar between ACWY -naïve and ACWY -experienced MenABCWY 
recipients.  During the same period, similar proportions of participants reported SAEs 
(1.1% vs 0.8%, respectively ), MAEs (26.2% vs 26.7%, respecti vely),and NDCMCs 
(0.4% vs 0.8%, respectively ).  Based on the immunogenicity  and safety  results from Study 
B1971057 outlined above, the benefit- risk profile for MenABCWY generated by  Phase 2 
Study  B1971057 is favorable. 
2.3.Benefit/Risk Assessment
Trumenba and Nimenrix are licensed vaccines, and common AEs noted after vaccination are 
primarily  related to reactogenicity , including local reactions (pain, swelling, redness around 
the injection site) and s ystemic events (headache, fatigue, m yalgias, arthralgias, 
nausea/vomiting, diarrhea, chills, fever). As noted above, the MenABCWY profile from the 
Phase 2 portion of Study  B1971057 is consistent with these 
2 licensed products.
As with any vaccine, an allergic reaction may  occur. Symptoms of an allergic reaction can 
include swelling of the lips, mouth, and throat, which may  cause difficult y in swallowing or 
breathing; skin rash; swelling of the hands, feet, and ankles; dizziness; and fainting. A severe 
allergic shock (anaph ylactic shock) may  occur. There may  also be additional risks related to 
the vaccines administered in the study  that are unknown at this time.
Risks that may  be associated with study  procedures include risk from blood sampling, such 
as feeling faint, dizziness, fainting, pain, swelling, bruising , and infection in the vicinity  of 
the vein from where blood is taken.  
Safety  assessments described in this protocol and ongoing safet y data reviews by the 
investigator, and the sponsor’s global medical monitor, the internal safety  data review 
s
ubcommitt ee, the internal risk management committee ,and the external data monitoring 
committee (E-DMC) will serve to monitor and mitigate these risks. 
In Phase 2 Study  B1971057, MenABCWY provided a high degree of immunologic 
protection against IMD caused b y N meningitidis serogroups A, B, C, W ,and Y using the 
accepted surrogate marker for protective immunity, hSBA ≥ LLOQ ,and was statistically  
noninferior to Trumenba for the B component and MenACWY -CRM for the ACWY 
components in both ACWY -naïve participants and ACWY -experienced participants . Both 
populations will be further evaluated to demonstrate noninferiorit y in the Phase 3 p
owered 
study .The proposed Phase 3 clinical trial for MenABCWY is the next step in the pathway  
for licensure, which , if successful, could provide a broadly  protective, safe, comprehensive, 
and first -in-class meningococcal vaccine that could contribute significantly to a simplified 
vaccination program for the prevention of IMD.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 26Pfizer therefore considers that the available information regarding licensed products 
Trumenba and Nimenrix , as well safet y and immunogenicity  results from Study  B1971057 
with MenABCWY, support a favorable benefit- risk profile for MenABCWY in this study .
More detailed information about the known and expected benef its and risks and reasonabl y 
expected AEs of MenABCWY may be found in the investigator’s brochure (IB), which is the 
single reference safet y document (SRSD) for this study. The SRSD is the US package insert 
(USPI ) for Trumenba and USPI  for MenACWY -CRM. 

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 273.OBJECTIVES, ESTIMAND S, AND ENDPOINTS
Objectives Estimands Endpoints
Primary Immunogenicity: Primary Immunogenicity: Primary Immunogenicity:
To demonstrate that the immune response for 
MenA, MenC, MenW, and MenY induced by 
2doses of MenABCWY is noninferior to the 
immune response induced by 1 dose of 
MenACWY -CRM in both ACWY -naïve and 
ACWY- experienced participants, separately .In ACWY -naïve participants receiving at least 1 dose (Group 2) of 
MenACWY -CRM or 2 dose s (Group 1) of MenABCWY and w ho are in 
compliance with the key protocol criteria (evaluable participants):
Difference in the percentage of seroresponders ,defined as participants 
achieving at least a 4-fold rise in hSBA titer from baseline for each 
ACWY te st strain, 1 month after Vaccination 2 in Group 1 compared to 
1 month after Vaccination 1 in Group 2.
For participants with a baseline hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold response is defined as a nhSBA titer 
of ≥1:16.
For particip ants with a baseline hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and LLOQ (ie, hSBA titer of 1:8), a 4 -fold 
response is defined as a nhSBA titer of ≥4 times LLOQ.
For participants with a baseline hSBA titer of ≥LLOQ, a 4 -fold 
response is defined as a nhSBA titer of ≥4 times the baseline titer.
In ACWY -experienced participants receiving at least 1 dose (Group 4) of 
MenACWY -CRM or 2 doses (Group 3) of MenABCWY and w ho are in 
compliance with the key protocol criteria (evaluable participants):
Difference in the percentage of seroresponders ,defined as participants 
achieving at least a 4-fold rise in hSBA titer from baseline for each 
ACWY test strain, 1 month after Vaccination 2 in Group 3 compared to 
1 month after Vaccination 1 in Group 4.  
For participants with a baseline hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold response is defined as a nhSBA titer 
of ≥1:16.
For participants with a baseline hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and LLOQ (ie, hSBA titer of 1:8), a 4-fold 
response is defined as a nhSBA titer of ≥4 times LLOQ.hSBA titer for each of the 
ACWY test strains.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 28Objectives Estimands Endpoints
For participants with a baseline hSBA titer of ≥LLOQ, a 4 -fold 
response is defined as a nhSBA titer of ≥4 times the baseline titer.
To demonstrate that the immune response for 
MenB induced by 2 doses of MenABCWY is 
noninferior to the immune response induced by 2 
doses of Trumenba .In participants receiving at least 2 doses of investigational product and who 
are in compliance with the k ey protocol criteria (evaluable participants):
Differences in the percentage of participants achieving an hSBA titer 
≥LLOQ (1:16 for strain A22 and 1:8 for strains A56, B24, and B44) 
for all 4 primary MenB test strains combined (composite response), in 
Groups 1 and 3 combined compared to Groups 2 and 4 combined, at 
1month after Vaccination 2. 
Difference in the percentage of participants achieving at least a 4-fold 
risein hSBA titer from baseline for each of the 4 primary MenB test 
strains, in Groups 1 a nd 3 combined compared to Groups 2 and 4 
combined, at 1 month after Vaccination 2.
For participants with a baseline hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold response is defined as an hSBA titer 
of ≥1:16.
For participants with a baseline hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and LLOQ, a 4 -fold response is defined as an 
hSBA titer of ≥4 times the LLOQ.
For participants with a baseline hSBA titer of ≥LLOQ, a 4 -fold 
response is defined as an hSBA titer of ≥4 times the baseline titer.hSBA titer for each of the 
primary MenB test strains 
(A22, A56, B24 ,and 
B44).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 29Objectives Estimands Endpoints
Primary Safety: Primary Safety: Primary Safety:
To describe the safety profile of MenABCWY, as 
measured by local reactions, systemic events, AEs, 
SAEs, NDCMC s, MAEs, and immediate AEs.In participants receiving at least 1 dose of investigational product, 
expressed in MenABCWY groups (Groups 1, 3, 5 ,and 7 combined) and 
Trumenba groups (Groups 2, 4, 6 ,and 8 combined):
The percentage of participants reporting local reactions, systemic 
events, and use of antipyretic medication within 7 days after each 
vaccination .
The percentage of participants reporting at least 1 SAE, at least 1 MAE ,
and at le ast 1 NDCMC during the following time periods:
30 Days after each vaccination.
30 Days after any vaccination.
During the vaccination phase (from the first study vaccination 
[Visit 1] through 1 month after the second study vaccination 
[Visit 4]).
During the follow -up phase (from 1 month after the second study 
vaccination [Visit 4] through 6 months after the second study 
vaccination [Visit 5]).
Throughout the study (from the first study vaccination [Visit 1] 
through 6 months after the second study vaccination [Visit 5]).
The percentage of participants reporting at least 1 AE during the 
following time periods:
30 Days after each vaccination.
30 Days after any vaccination.
During the vaccination phase (from the first study vaccination 
[Visit 1] through 1 month a fter the second study vaccination 
[Visit 4]).
The percentage of participants reporting at least 1 immediate AE.Local reactions (pain, 
redness, and swelling).
Systemic events (fever, 
vomiting, diarrhea, 
headache, fatigue, 
chills, muscle pain 
other than muscle pain 
at any injection site, 
and joint pain). 
Use of antipyretic 
medication .
AEs, SAEs, MAEs, 
NDCMCs, and 
immediate AEs .
Days missing from 
school or w ork because 
of AEs.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 30Objectives Estimands Endpoints
The percentage of participants who missed days of school or w ork 
because of AEs .
Secondary 
Immunogenicity:Secondary 
Immunogenicity:Secondary 
Immunogenicity:
To demonstrate that the immune response for 
MenA, MenC, MenW, and MenY induced by 
1dose of MenABCWY is noninferior to the 
immune response induced by 1 dose of 
MenACWY -CRM , in both ACWY -naïve and 
ACWY- experienced participants, separately .In ACWY -naïve participants receiving at least 1 dose of investigational 
product and w ho are in compliance with the ke y protocol criteria 
(evaluable participants):
Difference in the percentage of seroresponders ,defined as participants 
achieving at least a 4-fold rise in hSBA titer from baseline for each 
ACWY test strain, 1 month after Vaccination 1 in Group 1 compared to
Group 2.
For participants with a baseline hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold response is defined as a nhSBA titer 
of ≥1:16.
For participants with a baseline hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and LLOQ (ie, hSBA titer of 1:8), a 4 -fold 
response is defined as a nhSBA titer of ≥4 times LLOQ.
For participants with a baseline hSBA titer of ≥LLOQ, a 4 -fold 
response is defined as a nhSBA titer of ≥4 times the baseline titer.
In ACWY -experienced participants receiving at least 1 dose of 
investigational product and who are in compliance with the key protocol 
criteria (evaluable participants):
Difference in the percentage of seroresponders ,defined as participants 
achieving at least a 4-fold rise in hSBA titer from baseline for each 
ACWY test strain, 1 month after Vaccination 1 in Group 3 compared to 
Group 4.  
For participants with a baseline hSBA titer below  the LOD (or an 
hSBA titer of 1:4), a 4 -fold response is defined as a nhSBA t iter 
of ≥1:16.hSBA titer for each of the 
ACWY test strains.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 31Objectives Estimands Endpoints
For participants with a baseline hSBA titer of ≥LOD (ie, hSBA 
titer of ≥1:4) and LLOQ (ie, hSBA titer of 1:8), a 4 -fold 
response is defined as a nhSBA titer of ≥4 times LLOQ.
For participants with a baseline hSBA titer of ≥LLOQ, a 4 -fold
response is defined as a nhSBA titer of ≥4 times the baseline titer.
Tertiary/Exploratory: Tertiary/Exploratory: Tertiary/Exploratory:
To describe the immune response for MenA, 
MenC, MenW, and MenY induced by 2 doses of 
MenABCWY compared to the immune response 
induced by 1 dose of MenACWY -CRM , in both 
ACWY- naïve and ACWY- experienced 
participants, separately .In ACWY -naïve and ACWY -experienced participants separately who have 
received at least 1 dose (Groups 2 and 4) of MenACWY -CRM or 2 doses 
(Groups 1 and 3) of MenABCWY and who are in compliance w ith the key 
protocol criteria (evaluable participants):
The percentage of participants achieving an hSBA titer ≥1:8 for each 
ACWY test strain, at baseline, 1 month after Vaccination 1 in Groups 2 
and 4, and 1 month after Vaccination 2 in Groups 1 and 3.
The percentage of participants achieving hSBA titers of ≥1:8, ≥ 1:16, 
≥1:32, ≥1:64, and ≥1:128 for each ACWY test strain, at baseline, 
1month after Vaccination 1 in Groups 2 and 4, and 1 month after 
Vaccination 2 in Groups 1 and 3.
hSBA GMTs for each of the ACWY test strains, at baseline, 1 month 
after Vaccination 1 in Groups 2 and 4, and 1 month after Vaccination 2 
in Groups 1 and 3.hSBA titer for e ach of the 
ACWY test strains.
To describe the immune response for MenA, 
MenC, MenW, and MenY induced by 1 dose of 
MenABCWY compared to the immune response 
induced by 1 dose of MenACWY -CRM , in both 
ACWY- naïve and ACWY- experienced 
participants, separately .In ACWY -naïve and ACWY -experienced participants separately who have 
received at least 1 dose of investigational product and who are in 
compliance with the key protocol criteria (evaluable participants):
The percentage of participants achieving an hSBA titer ≥1:8 for each 
ACWY test strain, at baseline and 1 month after Vaccination 1 in 
Groups 1 through 4.
The percentage of participants achieving hSBA titers of ≥1:8, ≥ 1:16, 
≥1:32, ≥1:64, and ≥1:128 for each ACWY test strain, at baseline and 
1month after Vacc ination 1 in Groups 1 through 4.
hSBA GMTs for each of the ACWY test strains, at baseline and 
1month after Vaccination 1 in Groups 1 through 4.hSBA titer for each of the 
ACWY test strains.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 32Objectives Estimands Endpoints
To describe the immune response for MenB, as 
measured by hSBA performed w ith primary MenB 
test strains, induced by 2 doses of MenABCWY 
compared to the immune response induced by 2 
doses of Trumenba. In participants receiving at least 2 doses of investigational product who are 
in compliance with the key protocol criteria (evaluable participants):
The percentage of participants achieving an hSBA titer ≥LLOQ (1:16 
for A22 and 1:8 for A56, B24, and B44) for each primary MenB test 
strain in Groups 1 and 3 combined, and Groups 2 and 4 combined, at 
baseline and 1 month after Vaccination 2.
The percentage of participants w ith hSBA titers ≥1:4, ≥ 1:8, ≥1:16, 
≥1:32, ≥1:64, and ≥1:128 for each of the 4 primary MenB test strains in 
Groups 1 and 3 combined, and Groups 2 and 4 combined, at baseline 
and 1 month after Vaccination 2.
hSBA GMTs for each of the 4 primary MenB test strains in Groups 1 
and 3 combined, and  Groups 2 and 4 combined, at baseline and 
1month afte r Vaccination 2.hSBA titer for each of the 
primary MenB test strains 
(A22, A56, B24 ,and 
B44).
To describe the immune response for MenB, as 
measured by hSBA performed w ith secondary 
MenB test strains, induced by 2 doses of 
MenABCWY.In participants receiving at least 2 doses of investigational product who are 
in compliance with the key protocol criteria (evaluable participants):
The percentage of participants achieving an hSBA titer ≥LLOQ for 
each secondary MenB test strain in Groups 1 and 3 combined, at 
baseline and 1 month after Vaccination 2.
The percentage of participants w ith hSBA titers ≥1:4, ≥ 1:8, ≥1:16, 
≥1:32, ≥1:64, and ≥1:128 for each secondary MenB test strain in 
Groups 1 and 3 combined, at baseline and 1 month after Vaccin ation 2.
hSBA GMTs for the secondary MenB test strains in Groups 1 and 3 
combined, at baseline and 1 month after Vaccination 2.hSBA titer for each 
secondary MenB test 
strain.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 334.STUDY DESIGN
4.1.Overall Design
This is a Phase 3, randomized, active -controlled, observer -blinded multicenter trial in which 
approximately  2413 participants ≥10 to <26 y ears of age will be randomly  assigned to 
receive either MenABCWY and saline, or Trumenba and MenACWY -CRM ,as shown in 
Table 1.  The study will include evaluation of both ACWY -naïve and ACWY - experienced 
individuals.  All participants will be naï ve to any meningococcal group B vaccine prior to 
enrollment.
Participants in Groups 1 through 4 will be considered an immunogenicity  subset, and will 
contribute to both the safety  and immunogenicity  anal yses; these participants will have blood 
drawn prior to Vaccination 1 and 1 m onth after Vaccinations 1 and 2.  Participants in 
Groups 5through 8 will be considered a safet y subset and will contribute to the safet y 
analysis onl y, and will not have blood drawn for immunogenicit y evaluations.
Randomization will be stratified b y prior vaccination history .  Overall , a pproximately  
1225 ACWY -naïve and 1188 ACWY -experienced participants (having received 1 dose of 
Menactra or Menveo ≥4 years prior to the date of randomization) will be enrolled.  Of these
total participants , up to 675 ACWY - naïve and 1013 ACWY - experienced participants will 
contribute to the immunogenicity  subset.
Participants enrolled in the immunogenicity subset will contri bute to both immunogenicit y 
and safet y evaluations. Additionally , participants will be enrolled ina safety subset that will 
contribute exclusively  to the 
safet y evaluation. Numbers enrolled inthe safety  subset will 
therefor e be based on numbers needed to achieve anoverall number of enrolled participants,
all of whom will contribute to the safet y evaluat ion. Numbers stated in the protocol to be 
enrolled b y group across immunogenicit y and safety subsets ( Section 1.2 and Table 1) are 
estimates only . 
Additionally , randomization will be stratified by  geographic region.
  The overall participant 
distribution by  region will be approximately  80% from the US and approximately 20% from 
other regions. Among the participants in the immunogenicity subset, approximately 80% 
will be enrolled inUS investigative sites, and approxi mately
 20% will be enrolled in other 
regions.  
Regional or safety /immunogenicity  group enrollment shifts may  be necessary  based 
on the availability  of participants with specific characteristics (age group or ACWY 
experience) in a given location based on lo cal immunization practices. However, these 
minor shifts from the originall y targeted numbers will not deviate from original targets to a 
degree that will impact the overall stud y design or endpoint assessments of the study.
Enrollment targets will also be adjusted to achieve appropriate representation by  age group 
(participants 10 to 18 years old and participants 18 to 26 years old) within each subset, and 
ACWY strata within each subset.  

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 34Table 1. Study Design
Vaccination 1 Follow -
up
Visit 1aVaccination 2 Follow -up
Visit 2aTelephone 
Contact
Approximate 
Month0 1 6 7 12
Visit Number 1 2 3 4 5
ACWY-naïve 
participantsGroup 1 
(n=450)MenABCWY +
salineMenABCWY
Group 2 
(n=225)Trumenba +
MenACWY -CRMTrumenba
ACWY-
experienced 
participantsGroup 3  
(n=675)MenABCWY +
salineMenABCWY
Group 4 
(n=338)Trumenba +
MenACWY -CRMTrumenba
Blood draw
(Groups 1 -4 
only)25mL 25mL 25mLor 
50mL
ACWY-naïve 
participantsGroup 5 
(n=500)MenABCWY +
salineMenABCWY
Group 6 
(n=50)Trumenba +
MenACWY -CRMTrumenba
ACWY-
experienced 
participantsGroup 7 
(n=125)MenABCWY +
salineMenABCWY
Group 8 
(n=50)Trumenba +
MenACWY -CRMTrumenba
a.Follow -up Visits 1 and 2 will be a telephone contacts for safety -assessment -only participants in Groups 5through 8, 
for whom blood samples will not be obtained.
A portion of the projected number of participant enrollment slots may  bemoved from the 
safet y subset to the immunogenicity subset to achieve appropriate regional distribution for 
the overall stud y population and the immunogenicity subset.  This determination will be 
made b y the sponsor while still blinded . The sponsor may  decide to proceed with less than 
full enrol lment if an assessment of power shows that it is sufficient to meet the primary  
objectives. This assessment will be done in a completely  blinded fashion before any  
participants are unblinded or the immunogenicit y data areaccessed.
4.1.1. Approximate Duration of Participation for Each Participant
Each participant will participate in the study  for approximately  12 months. 
4.1.2. Approximate Number of Participants
Approximately  2413 participants will be enrolled.
4.2.Scientific Rationale for Study Design
In Study B1971057, a nFIH and POC study  for MenABCWY, 543 participants received 
MenABCWY on a 0
-month and 6 -month schedule.  Results from B1971057 indicated 
MenABCWY is well tolerated wit h an acceptable safet y profile, and also provides a high 
degree of protective immune responses among both ACWY -naïve and ACWY -experienced 
participants without interference among all 5 serogroup components.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 35The aim of this Phase 3 study  is to determine the immunologic noninferiority  of 
MenABCWY, an investigational pentavalent (serogroups A, B, C, W, and Y) meningococcal 
vaccine, to licensed vaccines Trumenba and Menveo (MenACWY- CRM) by  assessing the 
safet y and immunogenicity  of MenABCWY and the comparators i n healthy  participants 
≥10 to <26 y ears of age who are both ACWY -naïve and ACWY -experienced.
Data obtained from prior studies evaluating MenABCWY, MenACWY -TT (Nimenrix) ,and 
Trumenba support a favorable benefit -risk assessment for continued study of MenAB CWY.
4.3.Justification for Dose
Bivalent rLP2086 (120 µg, meningococcal group B vaccine) and MenACWY -TT (5 µg of 
each of the 4meningococcal pol ysaccharides A, C, W -135, and Y conjugated to 44 µg of 
tetanus toxoid) are available commerciall y as Trumenba and Ni menrix, respectivel y.  
Trumenba is indicated for active immunization to prevent invasive disease caused b y MenB , 
and is approved for use in Europe in individuals 10 y
ears of age and older and in the 
United States in individuals 10 through 25 years of age. Nimenrix is indicated for active 
immunization to prevent invasive disease caused by MenA, MenC, MenW, and Men Y , and 
is approved for use in Europe and a number of ex- US countries, in individuals 6 weeks of age 
and older.  Trumenba is supplied as a 0.5 -mL dose PFS, while Nimerix is supplied as a 
single -dose vial containing l yophilized powder to be reconstituted for injection.
MenABCWY consists of bivalent rL P2086, supplied as a 0.7
-mL PFS, which is used to 
reconstitute MenACWY- TT, and 0.5 mL  of the resultan t MenABCWY is administered via 
intramuscular injection.
The safet y, tolerability , and immunogenicit y of Trumenba and Nimenrix are well established 
in adolescents and young adults when used separately.  Results from Study B1971057, which 
evaluated MenABCWY on a 0-month and 6- month schedule in adolescents and y oung 
adults, showed no clinically  significant difference in the tolerability  or safety  of 
MenABCWY when compared to Trumenba.  Furthermore, no interference was demonstrated 
for either MenB or ACWY responses when compared to licensed vaccines Trumenba and 
Menveo in the U nited States and the EU.  Therefore, Pfizer is proceeding with adolescent 
and adult Phase 3 development of MenABCWY with the dose used in Study B1971057.
4.4.End of Study Definition
A participant is considered to have completed the study  if he/she has completed all phases of 
the study  including Visit 5 (final telephone contact).
The end of the stud y is defined as the date of the last visit of the last participant in the study.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 365. STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participants are enrolled.  The 
following eligibility  criteria are designed to select participants for whom participation in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or e xemptions, are not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Male and female participants 10 and <26 yearsof age at the time of randomization.
Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Willing and able to comply  with scheduled visits, treatment plan, laboratory tests, and 
other study  procedures.
3.ACWY
-naïve p articipants : Participants who have never received a prior dose of a 
meningococcal vaccine containing ACWY serogroups.  Written confirmation of 
vaccination history  must be obtained prior to randomization. 
ACWY-e xperienced participants: Participants who have received not more than 1 prior 
dose, no sooner than 4 years prior to the date of randomization of Menactra or Menveo.  
Written confirmation of vaccination history  must be obtained prior to randomization.
4.Available for the entire study  period and can be reached by  telephone.
5.Health y participant as determined by medical history, ph ysical examination, and
judgment of the investigator.
6.Male and female participants of childbearing potential must agree to use a highl y 
effective method of contraception for at least 28 day s after the last study  vaccination.  A 
participant is of childbearing potential if, in the opinion of the investigator, he/she is 
biologicall y capable of having children and is sexually active ( Appendix 4 ).
7. Negative urine pregnancy  test for all female participants; pregnancy  test is not applicable 
to male participants.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 37Weight:
Not applicable .
Informed Consent:
8.Capable of giving signed informed consent as described in Appendix 1 , which includes 
compliance with the requirements and restrictions listed in the informed consent 
document (ICD) and in this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.A previous anaph ylactic reaction to an y vaccine or vaccine -related component.
2. Bleeding diathesis or condition associated with prolonged bleeding time that would 
contraindicate intramuscular injection.
3.A known or suspected defect of the immune s ystem that would prevent an immune 
response to the vaccine, such as participants with congenital or acquired defects in B -cell 
functi on, those receiving chronic s ystemic (oral, intravenous, or intramuscular) 
corticosteroid therap y, or those receiving immunosuppressive therap y.  Participants in the 
United States with terminal complement deficiency  are excluded from participation in 
this study .  Please refer to the study  reference manual ( SRM) for additional details.
4.History  of microbiologically  proven disease caused by  N meningitidis or 
Neisseria gonorrhoeae .
5.Significant neurological disorder or history  of seizure (excluding simple febril e seizure).
6.Any neuroinflammatory  or autoimmune condition, including, but not limited to, 
transverse m yelitis, uveitis, optic neuritis, and multiple sclerosis.
7.Other acute or chronic medical or ps ychiatric condition including recent (within the past 
year) or active suicidal ideation ,recent (within the past y ear) hospitalization for 
psychiatric illness
,or behavior or laboratory  abnormality  that may  increase the risk 
associated with study participation or investigational product administration or may  
interf ere with the interpretation of study  results and, in the judgment of the investigator, 
would make the participant inappropriate for entry into this study .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 38Prior/Concomitant Therapy:
8.Previous vaccination with any  meningococcal group B vaccine, any purel y 
polysaccharide (nonconjugate) meningococcal vaccine, or monovalent/bivalent 
meningococcal vaccine.  Written vaccination history  must be obtained prior to 
randomization.
9.Participants receiving any  allergen immunotherapy  with a nonlicensed product or 
receivin g allergen immunotherap y with a licensed product and are not on stable 
maintenance doses.
10.Receipt of an y blood products, including immunoglobulin, within 6 months before the 
first study  vaccination.
11.Current use of s ystemic antibiotics with no foreseeable date of discontinuation prior to 
anticipated date of enrollment (first vaccination). 
Prior/Concurrent Clinical Study Experience:
12.
Participation in other studies involving investigational drug(s) or investigational 
vaccine(s) within 28 days prior to study  entry and/or during study  participation.
Diagnostic Assessments:
Not applicable .
Other Exclusions:
13.Investigator site staff members directl y involved in the conduct of the study and their 
family  members (including grandchildren) , site staff members otherwise supervised b y 
the investigator, or Pfizer employ ees, including their famil y members, directly involved 
in the conduct of the study . 
14.Pregnant female participants; breastfeeding female participants; fertile male participants 
and female participants of childbearing potential who are unwilling or unable to use a 
highl y effective method of contraception.
5.2.1. Temporary Delay Criteria
5.2.1.1. Criteria for Temporarily Delaying Vaccine Administration
The following conditions are temporary  or self-limiting and a participant may  be vaccinated 
once the conditions have resolved and the participant is eligible for vaccination:
1.Current febrile illness (temperature ≥38.0°C [100.4 °F]) or other acute illness within 
48hours before investigational produ ct administration.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 392.Participant has received any  nonlive vaccine (or intramuscular/sublingual allergen 
immunotherapy ) within 14 days, or any  live vaccine within 28 days, before 
investigational product administration (see exception below for an y COV ID-19 
vaccination) .
Guidance provided b y the US Center sfor Disease Control and Prevention (CDC) states 
that COVID -19 vaccines and other vaccines may  now be administered without regard to 
timing. Because of the COVID -19 pandemic and the ongoing COVID - 19 vaccinations 
at the time of study  recruitment, participants will be allowed to receive any authorized 
(
nonexperimental) COVID -19 vaccination within 8 day s of investigational product 
administration (ie,not permitted 7 day s before or after any  study  vaccination )
.
3. Participant is less than 5 days into a course of s ystemic antibiotic therapy .
4. Participant has received systemic (oral, intravenous, or intramuscular) corticosteroid 
therap y within the previous 28 days.
If a participant meets an y delay  criteria for vaccinat ion, all study  procedures, including blood 
sample collection relating to that visit, should be delay ed until the day  of vaccination.  Blood 
samples must alway s be collected prior to vaccination.
5.2.1.2. Criteria for Temporarily Delaying Immunogenicity Blood Draw
The following condition is temporary  or self -limiting and blood may  be drawn once the 
condition has resolved and the participant is eligible for blood collection:
1. Participant has received systemic antibiotic therapy  within the last 5 day s (must have a 
full 5- day interval between the date of the last dose and the date of blood collection).
5.3.Lifestyle Considerations
5.3.1. Contraception 
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an app ropriate method of contraception for the individual 
participant from the permitted list of contraception methods (see Appendix 4 ,Section 10.4.4) 
and will confirm that the participant has been instructed in its consistent and correct use.  At 
time points indicated in the SoA, the investigator or designee will inform the 
participant of 
the need to use highl y effective contraception consistently  and correctly  and document the 
conversation and the participant’s affirmation in the participant’s chart (participants need to 
affirm their consistent and correct use of at least 1 of the selected methods of contraception).  
In addition, the investigator or designee will instruct the participant to call immediately  if the 
selected contraception method is discontinued or if pregnancy  is known or suspected in the 
participant or partner .
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to investigational product/entered in the study .  

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001Final Protocol Amendment 2, 13 June 2022
PFIZER CONFIDENTIAL
Page 40Screen failure data are collected and remain as source and are not reported to the clinical 
database.
Individuals who do not meet the criteria for participation in this study (screen failure) may
not be rescreened. 
6. STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.
For the purposes of this protocol, the term investigational product may be used 
synonymously with study intervention.
6.1. Study Intervention(s) Administered
Trumenba is a 0.5-mL dose supplied as a PFS and formulated to contain 60 μg each of a 
purified subfamily A and a purified subfamily B rLP2086 protein, 0.15 M sodium chloride, 
 polysorbate 80, and 0.25 mg of Al
3+as aluminum phosphate (AlPO 4) in 
10 mM histidine-buffered saline at pH 6.0.
MenACWY-TT is supplied as a single-dose vial containing lyophilized powder to be 
reconstituted for injection.  The vaccine is formulated on the basis of purified capsular polysaccharide content and the amount of protein carrier is dependent on the polysaccharide-to-protein ratio.  The vaccine is nonadjuvanted and preservative-free.  
MenACWY-TT will be reconstituted with bivalent rLP2086 supplied as a 0.7-mL PFS, as 
detailed in the investigational product manual (IP manual), and 0.5 mL of the resultant MenABCWY will be administered via intramuscular injection.  The final MenABCWYvaccine composition includes rLP2086 subfamily A and B proteins formulated at 120μg/mL/subfamily, purified capsular polysaccharides of N meningitidis serogroups A, C, 
W, and Y at concentration of 10 μg/mL/polysaccharide type conjugated to tetanus toxoid at 
ratios of ~1:3, ~1:3, ~1:1.5, and ~1:1.3, respectively, in 10 mM histidine and 1.2 mM Tris buffer containing 150 mM sodium chloride, 0.5 mg/mL aluminum as AlPO
4, 0.035 mg/mL 
polysorbate 80, and 56 mg/mL sucrose.
MenACWY-CRM (Menveo) is supplied in 2 vials that must be combined prior to 
administration: the MenA lyophilized conjugate vaccine component is reconstituted with the 
meningococcal group C, Y, and W-135 (MenCYW-135) liquid conjugate vaccine component 
immediately before administration as a 0.5-mL intramuscular injection.
The placebo is sterile normal saline solution for injection and will be administered as a 
0.5-mL intramuscular injection.CCI
PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 41Intervention Name Trumenba MenABCWY MenACWY-CRM Placebo
(Normal Saline)
Dose Formulation Prefilled syringe 0.5 mL MenACWY -TT will 
be reconstituted with 
bivalent rLP2086, 
supplied as a 
0.7-mLPFS2 vials Sterile normal saline 
solution for injection 
Dosage Level(s) 0.5-mL dose at Visits1 
and 30.5_mL dose at Visits
1 and 30.5-mL dose at Visit10.5-mL dose at Visit1 
Route of 
AdministrationIntramuscular Intramuscular Intramuscular Intramuscular
Investigational 
Medicinal Product 
(IMP) and 
Noninvestigational 
Medicinal Product 
(NIMP)IMP IMP IMP IMP
Sourcing Pfizer Pfizer Commercial Pfizer
Packaging and 
LabelingStudy intervention will be 
provided in a single -dose 
PFS.  Each syringe will 
be packaged in a carton 
with a blinded label and a 
tamper -evident seal, and 
will be labeled as required 
per country requirement.Each MenABCWY 
kit will consist of a 
vial of 
MenACWY -TT, 
bivalent rLP2086 
0.7-mL PFS, and vial 
adaptor. Kits will be 
packaged in a carton 
with a blinded label 
and a tamper -evident 
seal, and will be 
labeled as required per 
country requirement.Study intervention will 
be provided in vials.  
The vials will be 
packaged in a carton 
with a blinded label 
and a tam per-evident 
seal, and will be 
labeled as required per 
country requirement .Study intervention will 
be provided in a 
single -dose PFS.  Each 
syringe will be 
packaged in a carton 
with a blinded label 
and a tamper -evident 
seal, and will be 
labeled as required per 
country requirement .
6.1.1. Administration
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of investigational products should be performed b y an appropriately 
qualified, Good Clinical Practice (GCP)- trained, and vaccine -experienced member of the 
study  staff (eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, pharmacist, or 
medical assistant) as allowed b y local, state, and institutional guidance. 
Investigational product administration details will be recorded on the case report form (CRF).
Table 2describes the administration details for each vaccine.  Each vaccine will be 
administered as a 0.5 -mL dose in the upper deltoid muscle of the left or right arm.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 42Table 2. Investigational Product Administration Schedule
Investigational Product Group(s) Visit(s) Upper Deltoid Muscle 
Injection Location
Trumenba 2, 4, 6 ,and 8 1 and 3 Left arm
MenABCWY 1, 3, 5 ,and 7 1 and 3 Left arm
MenACWY -CRM 2, 4, 6 ,and 8 1 Right arm
Placebo 1, 3, 5 ,and 7 1 Right arm
6.1.2. Medical Devices
In this stud y, medical devices being used will be the vial adaptor for MenABCWY, as well as 
the PFSs for placebo and Trumenba.
Instructions for medical device use are provided in the I P manual.
Medical device incidents, including those resulting from malfunctions of the device, must be 
detected, documented, and reported b y the unblinded study  personnel throughout the study .  
6.2.Prep aration/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study  interventions received and any  discrepancies are 
reported and resolved before use of the study  intervention, as applicable for 
temperature -monitored shipments.
2.Investigational product will be shipped to the study  site after required regulatory  and 
legal documents have been received b y the sponsor.  These will be shipped at +2 °C to 
+8°C.  Upon receipt at the study  site, the investigational product should be immediately  
transferred to a +2 °C to +8°C temperature -monitored refrigerator for storage.
3.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention.  All study 
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage conditions 
with access limited to the investigator and authorized site staff.  At a minimum, daily  
minimum and maximum temperatures for all site storage locations must be documented 
and available upon request.  Data for nonworking days must indicate the minimum and 
maximum temperature sinc e previousl y documented for all site storage locations upon 
return to business.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 434. The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).  All study interventions will be 
accounted for using an investigational product accountability form/record. Used needles 
and sy ringes should be disposed of according to local practi ce.  Empt y outer 
investigational product containers must be retained until reviewed by  the sponsor's 
representative and then may  be destroy ed after the sponsor’s representative has 
performed accountability.  I nvestigational product return/destruction must be 
documented on the accountability log.
5.Further guidance and information for the final disposition of unused study  interventions 
are provided in the IP manual.
6.Any storage conditions stated in the SRSD will be superseded by  the storage conditions 
stated on the product label.
7.Study  interventions should be stored in their original containers and in accordance with 
the labels.
8.See the IP manual for storage conditions of the study  intervention once reconstituted.
9.Any excursions from the study  intervention label storage conditions should be reported 
to Pfizer upon discovery  along with an y actions taken.  The site should actively  pursue 
options for returning the study  intervention to the storage conditions described in the 
labeling, as soon as possible.  Once a n excursion is identified, the study  intervention 
must be quarantined and not used until Pfizer provides permission to use the study  
intervention.  I t will not be considered a protocol deviation if Pfizer approves the use of 
the study  intervention after the temperature excursion. Use of the stud y intervention 
prior to Pfizer approval will be considered a protocol deviation. Specific details 
regarding the definition of an excursion and information the site should report for each 
excursion will be provided to the site in the IP manual.
10. Receipt of materials, door opening and closing, and other routine handling operations 
where the products are briefly  out of the temperature range described in the labeling are 
not considered excursions.
11.The sponsor or designe e will provide guidance on the destruction of unused study  
intervention (eg, at the site).  If destruction is authorized to take place at the investigator 
site, the investigator must ensure that the materials are destro yed in compliance with 
applicable env ironmental regulations, institutional policy , and any  special instructions 
provided by Pfizer, and all destruction must be adequatel y documented.
Additional details about accountability , storage, destruction, and excursion reporting can be 
found in the IP manual .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 446.2.1. Preparation and Dispensing
See the IP manual for instructions on how to prepare the investigational product for 
administration.  I nvestigational product should be prepared and dispensed by  an unblinded 
appropriatel y qualified and experienced member of the study  staff (eg, phy sician, nurse, 
physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as 
allowed b y local, state, and institutional guidance. The investigational product will be 
administered to participants wh o are blinded.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Investigational Product
Allocation (randomization) of participants to vaccine groups will proceed through the use of 
an interactive response technology  (IRT) s ystem that is accessible 24 hours a day , 365 day s a 
year.  Having logged in, the site personnel (study  coordinator or specified designee) will be 
required to enter or select certain information including but not limited to the user’s 
identification (ID) and password, protocol number, the participant number, if the participant 
should be considered ACWY -naïve or -experienced, and the date of birth of the participant.  
The site personnel will then be provided with a participant randomization number and 
dispensable unit (DU) orcontainer number.  The randomization number and the date on 
which the randomization number was assigned will be recorded on the CRF.  Once 
participant numbers, DU numbers, and randomization numbers have been assigned, they  
cannot be reassigned.  The I RT system will provide a confirmation report containing the 
participant randomization number and DU or container number assigned.  The confirmation 
report must be stored in the site’s files.
The study -specific I RT reference manual will provide the contact i nformation and further 
details on the use of the IRT system.
6.3.2. Blinding of Site Personnel
In this observer -blinded study , the study  staff dispensing, preparing, and administering the 
vaccine will be unblinded.  All other study  and site personnel, including t he investigator, 
investigator staff, participants, and participants’ parent(s)/legal guardian, will be blinded to 
investigational product assignments.  In particular, the individuals who evaluate participant 
safet y will be blinded.  Because the investigati onal products are different in phy sical 
appearance, the investigational product syringes will be administered in a manner that 
prevents the stud y participants from identify ing the vaccine t ype based on its appearance.
The responsibility  of the unblinded di spenser and administrator must be assigned to an 
individual or individuals who will not participate in the evaluation of an y study  participants.  
Contact between the unblinded dispenser and study participants and unblinded administrator 
and study  participa nts should be kept to a minimum.  The remaining site personnel must not 
know investigational product assignments.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 456.3.3. Blinding of the Sponsor
Those study  team members who are involved in ensuring that protocol requirements for 
investigational product preparation, handling, allocation, and administration are fulfilled at 
the site will be unblinded for the duration of the study  (eg, unblinded study  manager, 
unblinded clinical research associate). An unblinded clinician who is not a direct member of 
the study  team will review unblinded protocol deviations.  All other study  team members and 
all laboratory  testing personnel performing serology  assay s will remain blinded to vaccine 
assigned/received throughout the study .  All laboratory  testing personnel performing 
serology  assay s will also remain blinded to visit number throughout the study .
6.3.4. Breaking the Blind
At the initiation of the study , the study  site will be instructed on the method for breaking the 
blind.  The method will be either a manual or an electronic pr ocess.  Blinding codes should 
only be broken in emergency  situations for reasons of participant safet y.
In case of an emergency , when knowledge of the investigational product assignment is 
required for the medical management of an individual participant, i t may  be unblinded.  The 
investigator must notify  a member of the study  team immediately  after determining that it is 
necessary  to unblind the assignment.  The investigator must also indicate in source 
documents that the blind was broken and provide the date and reason for breaking the blind.  
Any AE or SAE associated with breaking the blind must be recorded and reported as 
specified in this protocol.
6.4. Study Intervention Compliance
All doses of investigational product will be administered by  the appropriately  designated 
study  staff at the investigator site.
6.5.Concomitant Therapy
The name and date of administration of any  nonstudy  vaccine (or allergen immunotherapy ) 
given from the signing of the I CD up to Visit 4 (approximately  1 month after Vaccinat ion 2) 
will be recorded on the CRF .
The name, start and stop dates, and route of administration for concomitant medications 
(prescription and nonprescription) used to treat an AE (excluding events recorded onl y in the 
e-diary ) from the signing of the I CD t o Visit 5 will be recorded in the CRF.
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are wome n of childbearing potential (WOCBP) (see Appendix 4 ).
6.5.1. Prohibited During the Study
Receipt of an y blood products, including immunoglobulin.
Nonstudy  meningococcal vaccines.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 46Nonlive or live nonstudy  vaccines are not permitted 14 and 28 day s, respectively , before 
or after an y stud y vaccination (see exception below for an y COV ID-19 va ccination) .
Guidance provided b y the US CDC states that COVID- 19 vaccines and other vaccines 
may now be administered without regard to timing. Because of the COVID -19 pandemic 
and the ongoing COVID -19 vaccinations at the time of study  recruitment, participants 
will be allowed to receive an y authorized ( nonexperimental) COVID -19 vaccination 
within 8 day s of investigational product administration (ie,not permitted 7 days before or 
after an y study vaccination ).
Intramuscular/sublingual allergen immuno therap y is not permitted within 14 days of an y 
study  vaccination.
Systemic (oral, intravenous, or intramuscular) corticosteroid therap y within 28 days of 
any study  vaccination.
6.5.2. Permitted During the Study
Nonstudy  vaccines used in the event of a disease out break or pandemic are allowed.  
However, while prioritizing standard clinical care, efforts should be made not to 
administer nonstudy  vaccines within 14 day s (for nonlive vaccines) or 28 day s (for live 
vaccine s) as specified below (see exception below for any COVID -19 vaccination).
Guidance provided b y the US CDC states that COVID- 19 vaccines and other vaccines 
may now be administered without regard to timing. Because of the COVID -19 pandemic 
and the ongoing COVID -19 vaccinations at the time of study  recru itment, participants 
will be allowed to receive an y authorized (nonexperimental) COVID -19 vaccination 
within 8 day s of investigational product administration (ie, not permitted 7 day s before or 
after an y study vaccination).
Nonstudy  vaccines (other than an y meningococcal vaccines) that are part of 
recommended immunization schedules are allowed any time during the study  but should 
not be administered within 14 days (for nonlive vaccines) and 28 day s (for live vaccines) 
of investigational product administration
Antipy retic and other pain medication to treat s ymptoms following investigational 
product administration is permitted.
A local anesthetic may  be used at the site of the blood draw.
Topical antibiotics are permitted.
Topical and inhaled corticosteroids ar e permitted.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 476.5.3. Prior Vaccinations and Treatments
If the participant is known to have ever received a poly ribos ylribitol phosphate 
oligosaccharide of Haemophilus influenzae type b conjugated to outer membrane protein 
(PRP-OMP ) vaccine, the name of the vaccine and date of administration will be recorded on 
the CRF.
Only  participants who have never received a prior dose, or who have received not more than 
1prior dose no sooner than 4 years prior to the date of randomization, of Menveo or 
Menactra may be enrolled ( Section 5).  If the participant has received any  prior 
meningococcal vaccines or vaccines containing 1 or more ACWY group s, the trade name 
(ifknown) and date of administration will be recorded on the CRF.  Please refer to the SRM 
for a list of ACWY- containing vaccines that are or have been commercially available.  
Written confirmation of vaccination history  should be obtained prior to randomization.  
6.5.4. Prohibited Prior Treatments
Receipt of an y blood products, including immunoglobulin, within 6 months before the first 
study  vaccination.
6.6.Dose Modification 
Not a pplicable .
6.7.Intervention After the End of the Study
No interv
ention will be provided to study  participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the institutional review board (IRB)
/ethics committee (EC), or 
investigational product safet y problems, or at the discretion of Pfizer.  In addition, Pfizer 
retains the right to discontinue development of MenABC WY at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.  After 
notification, the investigator must contact all participating participants and the hospital 
pharmacy  (if applicable) immediately .  As directed by  Pfizer, all study  materials must be 
collected and all CRFs completed to the greatest extent possible.
7.2.Participant Discontinuation/Withdrawal From the Study 
A participant may  withdraw from the study  at an y time at his/her own request, or may  be 
withdrawn at a ny time at the discretion of the investigator for safety , behavioral, compliance, 
or administrative reasons.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 48If a participant does not return for a scheduled visit, every  effort should be made to contact 
the participant.  All attempts to contact the participant and information received during 
contact attempts must be documented in the participant’s source document.  I n any  
circumstance, every  effort should be made to document participant outcome, if possible.  
At the time of discontinuing ,please refer to the SRM and SoA for assessments to be 
collected at the time of study  discontinuation and follow -up and for an y further evaluations 
that need to be completed. 
Participants should be questioned regardi ng their reason for withdrawal.  The investigator or 
his or her designee should capture the reason for withdrawal in the CRF for all participants .
The participant should be requested to return for a final visit, if applicable, and the 
investigator will per form the procedures indicated for the next visit.  Any AEs or SAEs that 
are continuing at the time of withdrawal from the study should be followed until resolution 
or, in case of permanent impairment, until the condition stabilizes.  
A final telephone con tact 6 months after the last vaccination Section 8.10.1.5 for the 
collection of safety  information should be completed for all participants who withdraw or 
have been withdrawn after administration of investigational product, unless consent for 
further contact has been withdrawn, or the participant is lost to follow -
up. Participant 
withdrawal should be explained in the source docu ments, and should include whether the 
withdrawal is only  from further receipt of investigational product or also from study  
procedures and/or postvaccination study  follow -up.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples, but data alread y generated from the samples will continue to be available, and may 
be used to protect the integrity  of existing anal yses.  The investigator must document any  
such requests in the site study  records.
If the participant wit hdraws from the study  and also withdraws consent for disclosure of 
future information, no further evaluations should be performed and no additional data should 
be collected.  The sponsor may  retain and continue to use any  data collected before such 
withdra
wal of consent.
When a participant withdraws from the stud y because of an SAE, the SAE must be recorded 
on the CRF and reported on the Clinical Trial (CT) SAE Report.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.
7.3.Lost to Follow -up 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the stud y site.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 49The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study ;
Before a participant is deemed lost to follow- up, the investigator or designee must make 
every  effort to regai n contact with the participant (where possible, 3 telephone calls and, 
if necessary , a certified letter to the participant’s last known mailing address or local 
equivalent methods).  These contact attempts should be documented in the participant’s 
medical record;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  as a whole is handled as part of Appendix 1 .
8.STUDY ASSESSMENT S AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA.  Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria.  The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ens ure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant.  When a protocol- required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 50For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participants in this the immunogenicity  
subset of this study  is approximately  75 o r 100 mL(depending on the amount of blood the 
participant has agreed to colled at Visit 4 : 25 or 50 mL ).  The actual collection times of blood 
sampling may  change. 
8.1.Efficacy Assessments
Not applicable .
8.1.1. Immunogenicity Assessments
To facilitate immunogenici ty anal yses, participants in the immunogenicity  subset will have 
approximately  25 mL of blood collected at Visit 1 (prior to Vaccination 1) andVisit 2 
(1month after Vaccination 1) and 25 or 50 mL of blood collected at Visit 4 (1 month after 
Vaccination 2 ).Sera obtained from participants at all time points will be used in these 
assay s.  LOD and LLOQ titers for these assay s will be detailed in the statistical analysis plan
(SAP )
.For participants ≥16 y ears of age who consent to providing an additional 25 mL 
(total 50 mL) of blood at Visit 4, the additional sera will be used for further assay  
development and validation and may  be used to support current and ad hoc study  endpoint 
immunogenicit y anal yses.
8.1.1.1. MenA, MenC, MenW, and MenY Serum Bactericidal Assays
For assessment of the immune response to MenACWY- CRM and the ACWY components of 
MenABCWY, test strains specific for each of the ACWY groups (A [PMB 277], 
C
[PMB3204] , W [PMB6270] , Y [PMB3385] ) will be used in the hSBAs for determination 
of the immunogenicit y endpoints in this study .  
8.1.1.2. MenB Serum Bactericidal Assays
For assessment of the immune response to Trumenba and the B component of MenABCWY, 
4 primary  MenB test strains, PMB80 (A22), PMB2001 (A56), PMB2948 (B24), and 
PMB2707 (B44), will be used in the hS BAs for determination of the immunogenicity  
endpoints in this study .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 518.1.2. Biological Samples
Blood samples will be used only  for scientific research.  Each sample will be labeled with a 
code so that the laboratory  personnel testing the samples will not know the participant’s 
identity .  Samples that remain after performing assay s outlined in the protocol may  be stored 
by Pfizer.  Unless a time limitation is required by  local regulations or ethical requirements, 
the samples will be stored for up to 15 y ears after the end of the stud y and then destro yed.  
Ifallowed by the ICD, stored samples may  be used for additional testing to better understand 
the immune responses to the vaccine(s) under study in this protocol, to inform the 
development of other products, and/or for vaccine -related assay  work supporting vaccine 
programs.  No testing of the participant’s genetic material will be performed. 
The participant may  request that his or her samples, if still identifiable, be destroy ed at any  
time; however, an y data alrea dy collected from those samples will still be used for this 
research.  The biological samples may  be shared with other researchers as long as 
confidentiality  is maintained and no testing of the participant’s genetic material is performed.
A mechanism (eg, appropriate wording within the study  ICD) will be established that enables 
testing of serum samples obtained during the study to assess for the preexistence of select 
AEs reported during study participation.
8.2.Safety Assessments
Planned time points for all safety assessments are provided in the SoA .  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  concerns.
Any participant who received at least 1 dose of investigational product will be included in the 
evaluation for safet y.  The following safet y parameters will be assessed as described in the 
Study  Procedures section (Section 8.10) and Section 1.3:
Physical examination.
Reactogenicit y: solicited local reactions and s ystemic events, including fever.
Use of antip yretic medication.
Unsolicited AEs and SAEs.
A medical history  will be obtained and a phy sical examination will be performed on all 
participants at Visit 1 to establish a baseline.   When taking the medical history  and 
performing the ph ysical examination, particular care must be taken to note any  
neuroinflammatory  and autoimmune conditions, such as transverse m yelitis, uveitis, optic 
neuritis, and multiple sclerosis.  Significant med ical history  and observations from the 
physical examination will be documented on the CRF.  I n addition, a urine pregnancy  test 
will be performed on all female participants.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 52The safet y parameters include reactogenicit y, ie, both local reactions and systemi c events that 
occur in the 7 day s (Day s 1 to 7) after investigational product administration.  These 
prompted e -diary  events are:
Local reactions at the site of investigational product administration (redness, swelling, 
and pain).
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other 
than muscle pain at the injection site, and joint pain).
Local reactions, s ystemic events, and use of antipyretic medication associated with vaccine 
administration will be collected using an e -diary .  For events that resolve after Day  7, the end 
date will be collected in the CRF.  If a participant does not complete the e- diary  for 7 day s, 
end dates of local reactions, sy stemic events, or antipy retic medication use that were ongoing 
on the last day the e -diary  was completed by  the participant will be collected on the CRF.
Immediate AEs, defined as AEs occurring within the first 30 minutes after investigational 
product administration, will be assessed and documented on the AE CRF.  The time of ons et 
will be recorded for an y AEs that occur on the same day  as investigational product 
administration.
MAEs and NDCMC s will also be assessed throughout the study  and documented on the 
appropriate AE CRF.  A n MAE is defined as a nonserious AE that results in an evaluation at 
a medical facility .  An NDCMC is defined as a disease or medical condition, not previously  
identified, that is expected to be persistent or otherwise long- lasting in its effects.
AEs (serious and nonserious), NDCMC s, and visits to other m edical facilities will be 
assessed at stud y visits as specified in the SoA and reported as defined in Section 8.3.  
AE-
related hospitalizations, visits to other medical facilities, medication use, and day s of 
school or work missed will be collected and recorded in the CRF.  Hospitalizations and visits
to medical facilities not associated with an AE, such as elective hospitalizations, healthcare 
visits for preventive care, or routine ph ysical examinations, will not be collected.  
Non–AE-related concomitant medications and day s of school or work missed not associated 
with an AE will not be collected.  A Study  Visit/Telephone Contact AE Checklist will be 
used as a guide, will be completed at each scheduled study  visit/telephone contact, and will 
be included in the source documentation.  Please refer to th e SRM for details.
Participants will be given a memory  aid at Visit 3.  The memory  aid will be used to remind 
participants to review any  significant illnesses, hospitalizations, NDCMC s, or visits to a 
medical facility  with study  site personnel. Participan tsmay use the memory aid as needed 
during the telephone contact at Visit 5 to prompt recall of events.  These may be used to 
assist in reporting and discussion of events with study  staff, but these memory  aids will not 
be considered source documents and w ill not be collected at study  visits.  Only  information 
collected b y stud y staff as part of a stud y visit or telephone contact (Visit 5) will be included 
in the source documents and entered into the CRF.
In addition, AEs and SAEs will be collected as defin ed in 
Section 8.3.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 538.2.1. Electronic Diary
An e -diary  will be issued based on a personal digital assistant or equivalent technology , and 
used to monitor and record the participant’s local reactions, s ystemic events, and use of 
antipy retic medication for 7 days after each vaccination.  Grading scales for local reactions 
and sy stemic events are based on US Food and Drug Administration (FDA ) Guidance for 
Industry , Toxicity  Grading Scale for Healthy  Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials.14  The e -diary  allows recording of these assessments only  
within a fixed time -window, thus providing the accurate representation of the participant’s 
experience at that time .
For local reactions and sy stemic events that resolve after Day 7, the end date will be 
collected on the CRF.  If the e -diary  is not completed for 7 day s, the end dates of local 
reactions, s ystemic events, or antipy retic medication use that occurred during the 7 day s will 
be collected on the CRF.  The investigator or designee should contact the parent (s)/legal 
guardian or participant in order to obtain stop dates for an y solicited reactions or other 
solicited data ongoing on the last day  that the e -diary  was completed.
Data reported on the e
-diary  will be transferred electronicall y to the e -diary  vendo r (a trusted 
third party ), where they  will be available for review by  investigators at all times via an 
internet -based portal.  At intervals agreed upon between the vendor and Pfizer, these data 
will be transferred electronically  into Pfizer’s database for analysis and reporting.  These data 
do not need to be reported by  the investigator on the CRF.
Investigators will be required to review the e -diary data online at frequent intervals to 
evaluate participant compliance and as part of the ongoing safet y revi ew.
8.2.1.1. Local Reactions
Local reactions (redness, swelling, and pain) at the site of investigational product 
administration will be recorded dail y for 7 days (Day s 1 to 7) after each vaccination.  Onl y 
local reactions at the site of investigational product adm inistration on the left arm will be 
recorded.
8.2.1.1.1. Redness and Swelling
Redness and swelling will be measured and recorded in caliper units (range: 1 to 21+), and 
then categorized as none, mild, moderate, or severe based on the scale given in Table 3.  
Each caliper unit represents 0.5 cm.  A caliper will be issued with instructions for measuring 
any redness or swelling at the injection site.  The caliper will be used to meas ure and to 
report the largest diameter of a local reaction.  In the event that a caliper measurement is 
between 2 values, the higher value should be reported.  The measurements will then be 
recorded in the e -diary .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 54In the event the reaction exceeds the maximum size the caliper is able to measure 
(21 caliper units), the parent(s)/legal guardian or participant will also measure the 
maximum diameter of the redness and/or swelling at the injection site using the measur ing 
tape/ruler provided and report this immediately  to the investigator.  The parent(s)/legal 
guardian or participant will report the maximum diameter of the redness and/or swelling at 
the injection site to the investigator daily until the reaction becomes ≤21 caliper units.  These 
measurements will be recorded in the CRF.
Table 3. Grading of Redness and Swelling
None 0 to 2.0 cm (0 to 4 caliper units)
Mild 2.0 to 5.0 cm (5 to 10 caliper units)
Moderate 5.0 to 10.0 cm (11 to 20 caliper units)
Severe 10.0 cm ( 20 caliper units)
8.2.1.1.2. Pain
If the participant experiences injection site pain, the pain will be graded using the scale in 
Table 4.  The assessment will then be recorded in the e -diary .
Table 4. Grading of Pain
Mild Does not interfere with activity
Moderate Interferes with activity
Severe Prevents daily activity
8.2.1.2. Systemic Events
8.2.1.2.1. Temperature
A digital thermometer will be given to the parent(s)/legal guardian or the participant with 
instructions on how to measure the participant’s oral temperature at home.  Oral temperature 
will be collected at in the evening dail y for 7 days (Day  1 to Day  7) after each vaccination, 
and at an y time during the 7 day s when fever is suspected.  The highest temperature for each 
day will be recorded in the e -diary .  Fever is defined as temperature of ≥38.0 °C (100.4°F).
Temperature will be measured and recorded to 1 decimal place and then categorized 
according to the severit y scale in 
Table 5.
Table 5.Severity Scale for Fever
Temperature 38.0 °C to 38.4 °C (100.4 °F to 101.1 °F)
Temperature 38.5 °C to 38.9 °C (101.2 °F to 102.0 °F)
Temperature 39.0 °C to 40.0 °C (102.1 °F to 104.0 °F)
Temperature 40.0°C (104.0 °F)

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 558.2.1.2.2. Other Systemic Events
The e -diary  will be used to record the presence of other systemic events, including vomiting, 
diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, 
and joint pain daily  for 7 days (Day1 to Day 7) after each vaccination, using the scal es in 
Table 6.
Table 6. Grading of Other Systemic Events
Grade 1 (Mild)
Grade 2 (Moderate) Grade 3 (Severe)
Vom iting 1 to 2 times in 24 hours >2 times in 24 hours Requires IV hydration
Diarrhea 2 to 3 loose stools in 
24hours4 to 5 loose stools in 
24hours6 or more loose stools in 
24 hours
Headache Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Fatigue Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Chills Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Muscle pain (other than 
muscle pain at the injection 
site)Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Joint pain Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Abbreviation: IV = intravenous.
8.2.1.2.3. Use of Antipyretic Medication
The use of antip yretic medication will be recorded in the e -diary  daily  during the active 
safet y observation periods (Day  1 to Day  7) for each vaccination.
8.2.2. Pregnancy Testing 
Urine pregnancy  tests will have a se nsitivity  of at least 25 mIU/mL .  Pregnancy  tests will be 
performed in WOCBP at the times listed in the SoA, immediately  before the administration 
of the vaccine.  A negative pregnancy  test result will be required prior to the participant’s 
receiving the investigational product.  Pregnancy  tests may  also be repeated if requested b y 
IRBs/ECs or if required by  local regulations.
In the case of a positive confirmed pregnancy  at Visit 1, the participant will not be eligible 
for participation.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 56The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE or caused the participant to discontinue from 
the study  (see Section 7). 
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant/parent(s)/legal guardian begins from the time the partic ipant 
provides informed consent, which is obtained before the participant’s participation in the 
study  (ie, before undergoing an y stud y-related procedure and/or receiving investigational 
product), through and including Visit 4. At Visit 5, the participant will be contacted b y 
telephone to inquire about SAEs, MAEs, and NDCMCs, since Visit 4.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
Medical occurrences that begin before the start of study  intervention but after obtaining 
informed consent will be recorded on the Medical History /Current Medical Conditions 
section of the CRF, not the AE section.
Follow -up by  the investigator continues throughout and after the active collection period and
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
Investigators are not obligated to activel y seek AEs or SAEs after conclusion of the study  
participation .  However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
prom ptly notify  the sponsor.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period are reported to Pfizer 
Safety  on the Vaccine SAE Reporting Form immediatel y and under no circumstance should 
this exceed 24 hou rs, as indicated in Appendix 3 .  The investigator will submit any  updated 
SAE data to the sponsor within 24 hours of it being available.
SAEs occurring in a participant after the active collection period has ended are reported to 
Pfizer Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 578.3.1.2. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/c ontacts.  For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent d etermination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.  The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs , and investigators.
Investi gator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the IBand will notify  the I RB/EC, if appropriate according to local 
requirements.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 588.3.5. Exposure During Preg nancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.3.5.1. Exposure During Pre gnancy
Details of all pregnancies in female participants and, if indicated, female partners of male 
participants will be collected after the start of study intervention and until the end of stud y 
participation.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 4 .
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, e ctopic pregnancy ) are considered SAEs.
8.3.5.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the
Vaccine SAE Reporting Form .  An exposure during breastfeeding report is not created when 
a Pfizer drug specifically approved for use in breastfeeding women (eg, vitamins) is 
administered in accord with authorized use.  However, if the infant experiences a n SAE 
associated with such a drug’s administration, the SAE is reported together with the exposure 
during breastfeeding.
8.3.5.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare profes sional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the Vaccine SAE Repor ting Form , regardless of whether there is an 
associated SAE.  Since the information does not pertain to a participant enrolled in the study , 
the information is not recorded on a CRF; however, a cop y of the completed Vaccine SAE 
Reporting Form is maintained in the investigator site file.
8.3.6. Medical Device Incidents (Including Malfunctions )
Medical devices are being provided for use in this study  for the purposes of administering 
and preparing investigational product . In order to fulfill regulatory  reporting obligations 
worldwide, the unblinded site staff is responsible for the detection and documentation of 
events meeting the definitions of incident or malfunction that occur during the study  with 
such devices.
The definition of a medical device incident can b e found in Appendix 6.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 59NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Section 8.3.3 and Appendix 3 of the protocol.
8.3.6.1.
Time Period for Detecting Medical Device Incidents
Medical device incidents or malfunctions of the device that result in an incident will be 
detected, documented, and re ported during all periods of the study  in which the medical 
device is used.
If the investigator learns of an y incident at an y time after a participant has been discharged 
from the study , and such incident is considered reasonably  related to a medical device 
provided for the stud y, the investigator will promptly  notify  the sponsor.
The method of documenting medical device incidents is provided in Appendix 6.
8.3.6.2. Follow -up of Medical Device Incidents
All medical device incidents invo lving an AE will be followed and reported in the same 
manner as other AEs (see Section 8.3.3).  This applies to all participants, i ncluding those who 
discontinue study  intervention.
The unblinded site staff are responsible for ensuring that follow -up includes any  
supplemental investigations as indicated to elucidate the nature and/or causality  of the 
incident.
New or updated informati
on will be recorded on the originally  completed form with all 
changes signed and dated by  the unblinded site staff.
8.3.6.3. Prompt Reporting of Medical Device Incidents to Sponsor
Medical device incidents will be reported to the sponsor within 24 hours after the u nblinded 
site staff determines that the event meets the protocol definition of a medical device incident.
Information will be provided to the sponsor as described in the IP manual .
The same individual will be the contact for the receipt of medical device reports and SAEs.
8.3.6.4. Regulatory Reporting Requirements for Medical Device Incidents
The investigator will promptly  report all incidents occurring with any  medical device 
provided for us e in the study  in order for the sponsor to fulfill the legal responsibility  to 
notify  appropriate regulatory  authorities and other entities about certain safety  information 
relating to medical devices being used in clinical studies.
The investigator, or responsible person according to local requirements (eg, the head of the 
medical institution), will comply  with the applicable local regulatory  requirements relating to 
the reporting of incidents to the I RB/EC.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 608.3.7. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the investigational product under study  may  occur in clinical trial settings, such 
as medi cation errors.
Safety Event Recorded on the CRF Reported on the Vaccine SAE 
Reporting Form to Pfizer Safety 
Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do or 
do not involve the study  participant.
Other examples include, but ar e not limited to:
The administration of expired investigational product;
The administration of an incorrect investigational product;
The administration of an incorrect dosage;
The administration of investigational product that has undergone temperature exc ursion 
from the specified storage range, unless it is determined by the sponsor that the 
investigational product under question is acceptable for use.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a Vaccine SAE 
Reporting Form only when associated with an SAE.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 618.4.Treatment of Overdose
For this study , any  dose of investigational product greater than 1 dose of investigational 
product within a 24 -hour time period will be considered an overdose. Pfizer does not 
recommend specific treatment for an overdose. In the event of an overdose, the investigator 
should:
1.Contact the medical monitor immediately .
2.Closely  monitor th e participant for an y AEs/SAEs .
3.Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.
4.Overdose is reportable to Safety  only when associated with an SAE.
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.
8.5.Pharmacokinetics 
Not a pplicable .
8.6.Pharmacodynamics
Not applicable .
8.7.Genetics
Not a pplicable .
8.8.Biomarkers
Biomarkers are not evaluated in th is study .
8.9.Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study .
8.10. Study Procedures
8.10.1. Group 1 -
4 Participants - Immunogenicity Subset
8.10.1.1. Visit 1 (Day 1): Vaccination 1
In the case of temporary  delay  of vaccination, procedures and assessments below will be 
redone or reconfirmed, as applicable, on the day  of vaccination.
Obtain written informed consent, and assent if appropriate, before performing 
study -specific procedures.  The date of informed consent will be recorded on the CRF.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 62Record the participant’s demographic information (including date of birth, sex, race, and 
ethnicity ).  The full date of birth will be collected to critically  evaluate the immun e 
response and safet y profile by  age.
Record the presence of chronic conditions and/or medical history  of significance, 
including relevant surgical procedures and cardiac medical history .
Record previous PRP -OMP vaccinations as described in the Prior Vacci nations and 
Treatment ssection ( Section 6.5.3).
Record an y prior meningococcal vaccines or vaccines containing 1 or more ACWY 
groups as described in the Prior Vaccinations and Treatm entssection ( Section 6.5.3).
Perform ph ysical examination evaluating an y clinically significant abnormalities within 
the following bod y systems: general appearance; skin; head, ey es, ears, nose, throat; 
heart; lungs; abdomen; extremities; neurological; musculoskeletal; and ly mph nodes
; 
including worsening of medical history  conditions.  Results must be recorded on source 
documents and the CRF.  Findings from a ph ysical examination conducted as part of 
standard routine care and before informed consent may  be used for purposes of the stu dy 
only if the examination was performed no more than 2 day s before vaccination.  A brief 
examination must be performed on the day of vaccination to document that no change in 
health has occurred in the interim.
On the day  of vaccination, perform a urine p regnancy  test on female participants.  
Anegative pregnancy  test result is required before the participant may  receive the 
investigational product.
On the day  of and before vaccination, measure and record the participant’s oral 
temperature.
Ensure that all of the inclusion criteria, none of the exclusion criteria, and none of the 
temporary  delay  criteria are met.
If a participant is eligible for the stud y, randomize the participant using an interactive 
voice response sy stem ( IVRS) , interactive Web -based res ponse sy stem (IWRS), or an 
equivalent sy stem.
On the day  of and before vaccination, collect a blood sample (approximately  25 mL).  
Collect the blood sample only  if the participant is eligible for vaccination on the same 
day.
The unblinded administrator administers a single 0.5- mL intramuscular injection of either 
MenABCWY (Groups 1 and 3) or Trumenba (Groups 2 and 4) into the upper deltoid 
muscle of the left arm; and either MenACWY-CRM (Groups 2 and 4) or saline (Groups 1 
and 3) into the upper deltoid muscl e of the right arm.  The time of investigational product 
administration will be recorded on the CRF.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 63Observe the participant for at least 30 minutes (or longer as per local practice) after the 
investigational product administration for any  acute reactions.   Record an y AEs observed 
during the 30 -minute observation period ;these AEs are defined as immediate AEs 
(Section 8.2).
Record AEs as described in the AE 
reporting requirements section ( Section 8.3) and the
SoA.  Time of onset 
will be recorded for an y AEs that occur on the same day as 
investigational product administration.
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ysection ( Section 6.5).
Issue a participant e -diary  and provide instruction on its completion.  Ask the 
parent(s)/legal guardian or participant to complete the e -diary  from Day  1 to Day  7 after 
vaccinati on.  Day  1 is the day  of vaccination.
Issue a caliper, 
a measuring tape/ruler, and a digital thermometer and provide instructions 
on their use.
Measuring tape/ruler data must be collected by the parent(s)/legal guardian for minor 
participants.  All data mu st be recorded in the e -diary  by the parent(s)/legal guardian for 
minor participants.
Ask the parent(s)/legal guardian or the participant to use the caliper to measure the 
maximum diameter of redness and swelling at the left arm injection site each day  forthe 
7 day s after study  vaccination and record in the e -diary  as described in Section 8.2.1.1.1.
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if the participant experiences severe redness or swelling ( 20 caliper units) at the left arm 
injection site, a fever ≥
39.0°C (102.1°F), or a severe headache within 7 days after 
vaccination, as an uns
cheduled visit should be arranged ( Section 8.11).
If the reaction exceeds the maximum size the caliper is able to measure (>21 calipe r 
units), the parent(s)/legal guardian or the participant should also use the measuring 
tape/ruler to measure the maximum diameter of redness and/or swelling at the injection 
site, and report this immediately  to the investigator. 
Ask the parent(s)/legal g uardian or participant to report the maximum diameter of the 
redness and/or swelling at the injection site to the investigator daily  until the reaction 
becomes 
≤21 caliper units.
Provide the parent(s)/legal guardian or participant with a contact card ( Section 10.1.10).
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if any  significant illness 
or hospitalization occurs.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 64Schedule an appointment for the next study  visit and confirm that it is scheduled within 
the time window per protocol.
Remind the parent(s)/legal guardian or participant to bring the e -diary  to the next study  
visit.
Complete the source documents.
Complete the CRF and update the investigational product accountability  records.
Between visits, review the e -diary  data online at frequent intervals.  Contact the 
parent(s)/legal guardian or the participant to obtain stop dates for an y local reactions, 
systemic events, or use of antipy retic medication that were ongoing on the last day  that the 
e-diary  was completed.  The stop dates should be documented in the source documents and 
the information entered into the CRF at the next study  visit of the participant.
8.10.1.2. Visit 2 (28 to 42 Days After Visit 1), Post –Vaccination 1 Blood Draw
Ensure that the participant continues to be eligible for the study , and continues to comply  
with contraception requirements detailed in Section 5.
Ensure that the participant continues to meet none of the withdrawal criteria and none of 
the temporary  delay  of blood draw criteria as described in Section 5.2.1.
Collect the participant’s e
-diary .
Review the participant’s e -diary  data since the previous visit and follow up on any  
ongoing reactogenicity  or use of antipy retic medication.
Complete the Study  Visit/Telephone Contact AE Checklist to:
Inquire whether the participant had an y NDC M
Cssince the last visit.  I nquire 
whether the participant had an y of the following related to an AE since the last visit: 
hospitalizations, visits to other medical facilities, medication use, or missed day s of 
school or work.  Please refer to the SRM for add itional details.
Inquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis.  Please refer to the SRM for 
additional details.
Record AEs as described in the AE r eporting requireme nts section ( Section 8.3) and the
SoA.
Review AEs that were ongoing since the previous visit an d record their end dates or 
confirm that they  are still continuing.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 65Record nonstud y vaccinations as described in the Concomitant T herap ysection 
(Section 6.5).
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ysection ( Section 6.5).
Collect a blood sample (approximately  25 mL). 
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if any  significant illness or hospitalization oc curs.
Schedule an appointment for the next visit and confirm that it is scheduled within the 
time window per protocol.
Complete the source documents.
Complete the CRFs.
8.10.1.3. Visit 3 (173 to 194 Days After Visit 1): Vaccination 2
In the case of temporary  delay  of vaccination, procedures and assessments below will be 
redone or reconfirmed, as applicable, on the day  of vaccination.
Ensure that the participant continues to be eligible for the study , and continues to comply  
with contraception requirements detailed in Section 5.
Ensure that the participant continues to meet none of the withdrawal criteria as described 
in Section 5.2.1 and none of the temporary  delay  of vaccination or blood draw criteria as 
described in Section 5.2.1 .
Complete the Study  Visit/Telephone Contact AE Checklist to:
Inquire whether the participant had an y NDCMC s since the last visit.  I nquire 
whether the participant had an y of the fol lowing related to an AE since the last visit: 
hospitalizations, visits to other medical facilities, medication use, or missed day s of 
school or work.  Please refer to the SRM for additional details.
Inquire about neuroinflammatory and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis.  Please refer to the SRM for 
additional details.
Record AEs as described in the AE r eporting requirements section ( Section 8.3) and the
SoA.  Time of onset will be recorded for an y AEs that occur on the same day as 
investigational product administration.
Review AEs that 
were ongoing from the previous visit and record their end dates or 
confirm that they  are still continuing.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 66Record nonstud y vaccinations as described in the Concomitant T herap ysection 
(Section 6.5).
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ysection ( Section 6.5).
On the day  of vaccination, perform a urine pregnancy  test on female participants.  
Anegative pregnancy  test result is required before the participant may  receive the 
investigational product.
On the day  of and before vaccination, measure and record the participant’s oral 
temperature.
The unblinded administrator administers a single 0.5
-mL intramuscular injection of either 
MenABCWY (Groups 1 and 3) or Trumenba (Groups 2 and 4) into the upper deltoid 
muscle of th e left arm.  The time of investigational product administration will be 
recorded on the CRF.
Observe the participant for at least 30 minutes (or longer as per local practice) after the 
investigational product administration for any  acute reactions.  Record any AEs observed 
during the 30 -minute observation period; these AEs are defined as immediate AEs 
(Section 8.2).
Issue a participant e
-diary  and provide instruction on its completion.  Ask the 
parent(s)/legal guardian or participant to complete the e -diary  from Day  1 to Day  7 after 
vaccination. Day 1 is the day  of vaccination.
Issue a caliper, a measuring tape/ruler, and a digital ther mometer and provide instructions 
on their use.
Measuring tape/ruler data must be collected by the parent(s)/legal guardian for minor 
participants.  All data must be recorded in the e -diary  by the parent/legal guardian for 
minor participants.
Ask the parent (s)/legal guardian or the participant to use the caliper to measure the 
maximum diameter of redness and swelling at the left arm injection site each day  for the 
7 day s after study  vaccination and record in the e -diary  as described in Section 8.2.1.1.1.
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if the participant experiences a severe redn
ess or swelling ( 20 caliper units) at the left 
arm injection site, a fever ≥39.0°C (102.1°F), or a severe headache within 7 day s after 
vaccination, as an unscheduled visit should be arranged ( Section 8.11).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 67If the reaction exceeds the maximum size the caliper is able to measure ( 21 caliper 
units), the parent/legal guardian or the participant should also use the measuring 
tape/ruler to measure the maximum diameter of redness and/or swelling at the injection 
site, and report this immediately  to the investigator. 
Ask the parent(s)/legal guardian or participant to report the maximum diameter of the 
redness and/or swelling at the injection site to the investigator daily  until the reaction 
becomes ≤ 21 caliper units.
Provide the parent(s)/legal guardian or the participant with a memory  aid. Instruct the 
participant to use the memory  aid between Visits 4 and 5 to remind him or her to review 
any significant illnesses, hospitalizations, NDCMC s, or visits to a medical facility  with 
study  site personnel. The memory  aid is not a diary  for the collection of reactogenicit y.  
Please refer to the SRM for additional details.
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if any  significant illness or hospitalization occurs.
Schedule an appointment for the next study  visit and confirm that it is scheduled within 
the time window per protocol.
Ask the parent( s)/legal guardian or the participant to bring the e- diary  to the next visit.
Complete the source documents. 
Complete the CRF and update the investigational product accountability  records.
Between visits, review the e -diary  data online at frequent interval s. Contact the 
parent(s)/legal guardian or the participant to obtain stop dates for an y local reactions
,
systemic events, or use of antipy retic medication that were ongoing on the last day  that the 
e-diary  was completed.  The stop dates should be document ed in the source documents and 
the information entered into the CRF at the next study  visit of the participant.
8.10.1.4. Visit 4 (28 to 42 Days After Visit 3), Post –Vaccination 2 Blood Draw
Ensure that the participant continues to be eligible for the study , and con
tinues to comply  
with contraception requirements detailed in Section 5.
Ensure that the participant continues to meet none of the with drawal criteria and none of 
the temporary  delay  of blood draw criteria as described in Section 5.2.1 .
Collect the participant’s e- diary.
Review the participant’s e -diary  data since the previous visit and follow up on any  
ongoing reactogenicity  or use of antipy retic medication.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 68Complete the Study  Visit/Telephone Contact AE Checklist to:
Inquire whether the participant had an y NDCMC ssince the last visit.  I nquire 
whether the participant had an y of the following related to an AE since the last visit: 
hospitalizations, visits to other medical facilities, medication use, or missed day s of 
school or work.  Please refer to the SRM for add itional details.
Inquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis. Please refer to the SRM for 
additional details.
Record AEs as described in the AE r eporting requireme nts section ( Section 8.3) and the
SoA.
Review AEs that were ongoing since the previous visit an d record their end dates or 
confirm that they  are still continuing.
Record nonstud y vaccinations as described in the Concomitant T herap ysection 
(Section 6.5).
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ysection ( Section 6.5).
Collect a blood sample (approximately  25 mL [or 50 mL for the 
subset of consented 
participants ≥16 y ears of age ]).  
Ask the parent(s)/legal guardian or the participant to contact the inv estigator immediately  
if any  significant illness or hospitalization occurs.
Schedule a telephone contact and confirm that it is scheduled within the time window per 
protocol.
Complete the source documents.
Complete the CRFs.
8.10.1.5. Visit 5 (168 to 196 Days After Last Vaccination), Telephone Contact
This telephone contact should occur approximately  6 months after the last study  
vaccination; this contact should be attempted for all participants who have received at 
least 1 study  vaccination, unless they  have withdra wn consent.
Contact the parent(s)/legal guardian or the participant by  telephone.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 69Complete the Study  Visit/Telephone Contact AE Checklist to:
Inquire about SAEs, NDCMC s, or AEs that resulted in evaluation at a medical 
facility  since the last visit.  Please refer to the SRM for additional details.
Inquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis. A checklist will be provided 
as a guide. Please refer to the SRM for additi onal details.
Report an y SAEs to the sponsor as defined in Section 8.3.
Record AEs as described in the AE 
reporting requirements section ( Section 8.3) and the
SoA.
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ySection 6.5.
Review AEs that were ongoing since the previous visit and record their end dates or 
confirm that they  are still continuing.
Complete the source documents.
Complete the CRFs.
8.10.2. Group 5 -
8 Participants - Safety Subset
8.10.2.1. Visit 1 (Day 1): Vaccination 1
In the case of temporary  delay  of vaccination, procedures and assessments below will be 
redone or reconfirmed, as applicable, on the day  of vaccination.
Obtain written informed consent, and assent if appropriate, before performing 
study -specific procedures.  The date of informed consent will be recorded on the CRF.
Record the participant’s demographic information (including date of birth, sex, race, and 
ethnicity ).  The full date of birth will be collected to critically  evaluate the immune 
response and safet y profile by  age.
Record the presence of chronic conditions and/or medical history  of significance, 
including relevant surgical procedures and cardiac medical history .
Record previous PRP -OMP vaccinations as described in the Prior Vaccinations and 
Treatment ssection ( Section 6.5.3).
Record an y prior meningococcal vaccines or vaccines containing 1 or more ACWY 
groups as described in the Prior 
Vaccinations and Treatment ssection ( Section 6.5.3).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 70Perform ph ysical examination evaluating an y clini cally  significant abnormalities within 
the following bod y systems: general appearance; skin; head, ey es, ears, nose, throat; 
heart; lungs; abdomen; extremities; neurological; musculoskeletal; and ly mph nodes; 
including worsening of medical history  conditio ns.  Results must be recorded on source 
documents and the CRF.  Findings from a ph ysical examination conducted as part of 
standard routine care and before informed consent may  be used for purposes of the study  
only if the examination was performed no more than 2 day s before vaccination.  A brief 
examination must be performed on the day of vaccination to document that no change in 
health has occurred in the interim.
On the day  of vaccination, perform a urine pregnancy  test on female participants.  A 
negative pregnancy  test result is required before the participant may  receive the 
investigational product.
On the day  of and before vaccination, measure and record the participant’s oral 
temperature.
Ensure that all of the inclusion criteria, none of the exclusion criteria, and none of the 
temporary  delay  criteria are met.
If a participant is eligible for the stud y, randomize the participant using an IVRS, I WRS, 
or an equivalent s ystem.
The unblinded administrator administers a single 0.5- mL intramuscular injection of either 
MenABCWY (Groups 5 and 7) or Trumenba (Groups 6 and 8) into the upper deltoid 
muscle of the left arm; and either MenACWY-CRM (Groups 6 and 8) or saline (Groups 5 
and 7) into the upper deltoid muscle of the right arm.  The time of investigational product 
administration will be recorded on the CRF.
Observe the participant for at least 30 minutes (or longer as per local practice) after the 
investigational product administration for any  acute reactions.  Record any  AEs observed 
during the 30 -minute o bservation period ;these AEs are defined as immediate AEs 
(Section 8.2).
Record AEs as described in the AE 
reporting requirements sect ion (Section 8.3) and the
SoA.  Time of onset will be recorded for an y AEs that occur on the sa me day  as 
investigational product administration.
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ysection ( Section 6.5).
Issue a participant e -diary  and provide instruction on its completion.  Ask the 
parent(s)/legal guardian or participant to complete the e -diary  from Day  1 to Day  7 after 
vaccination.  Day 1 is the day  of vaccination.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 71Issue a caliper, a measuring tape/ruler, and a digital thermometer and provide instructions 
on their use.
Measuring tape/ruler data must be collected by the parent(s)/legal guardian for minor 
participants.  All data must be recorded in the e- diary  by the parent(s)/legal guardian for 
minor participants.
Ask the parent(s)/legal guardian or the participant to use the caliper to measure the 
maximum diameter of redness and swelling at the left arm injection site each day  for the 
7 days after study  vaccination and record in the e -diary  as described in Section 8.2.1.1.1.
Ask the parent(s)/legal guardian or the part icipant to contact the investigator immediately  
if the participant experiences severe redness or swelling ( 20 caliper units) at the left arm 
injection site, a fever ≥
39.0°C (102.1°F), or a severe headache within 7 days after 
vaccination, as an unscheduled visit should be arranged ( Section 8.11).
If the reaction exceeds the maximum size the caliper is able to measure ( 21 caliper 
units), the parent(s)/legal guardian or the participant should also use the measuring 
tape/ruler to measure the maximum diameter of redness and/or swelling at the injection 
site, and report this immediately  to the investigator. 
Ask the parent(s
)/legal guardian or participant to report the maximum diameter of the 
redness and/or swelling at the injection site to the investigator daily  until the reaction 
becomes ≤ 21 caliper units.
Provide the parent(s)/legal guardian or participant with a contact c ard (Section 10.1.10).
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if any  significant illness or hospitalization occurs.
Schedule an appointment for the next study  visit and confirm that it is scheduled within 
the time window per protocol.
Remind the parent(s)/legal guardian or participant to bring the e -diary  to the next study  
visit.
Compl ete the source documents.
Complete the CRF and update the investigational product accountability  records.
Between visits, review the e -diary  data online at frequent intervals.  Contact the 
parent(s)/legal guardian or the participant to obtain stop dates for an y local reactions, 
systemic events, or use of antipy retic medication that were ongoing on the last day  that the 
e
-diary  was completed.  The stop dates should be documented in the source documents and 
the information entered into the CRF at the next study  visit of the participant.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 728.10.2.2. Visit 2 (28 to 42 Days After Visit 1), Post –Vaccination 1 Telephone Contact
Visit 2 will be a telephone contact for participant in the safet y subset (Groups 5-8).
Ensure that the participant continues to be eligible for the s tudy, and continues to comply  
with contraception requirements detailed in Section 5.
Ensure that the participant continues to meet none of the withdrawal criteria and none of 
the temporary  delay  of blood draw criteria as described in Section 5.2.1.
Review the participant’s e -diary  data since the previous visit and follow up on any  
ongoing reactogenicity  or use of antipy retic medication .
Complete the Stud y Visit/Telephone Contact AE Checklist to:
Inquire whether the participant had an y NDCMC s since the last visit.  I nquire 
whether the participant had an y of the following related to an AE since the last visit: 
hospitalizations, visits to other medical facil ities, medication use, or missed day s of 
school or work.  Please refer to the SRM for additional details.
Inquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis.  Please refer to the SRM for 
additional details.
Record AEs as described in the AE 
reporting requirements section ( Section 8.3) and the
SoA.
Review AEs that were ongoing since the previous visit and record their end dates or 
confirm that they  are still continuing.
Record nonstud y vaccinations as described in the Concomitant T herap ysection 
(Section 6.5).
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ysection ( Section 6.5).
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if any  significant illness or hospitalization occurs.
Schedul e an appointment for the next visit and confirm that it is scheduled within the 
time window per protocol.
Complete the source documents.
Complete the CRFs .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 738.10.2.3. Visit 3 (173 to 194 Days After Visit 1): Vaccination 2
In the case of temporary  delay  of vaccination, procedures and assessments below will be 
redone or reconfirmed, as applicable, on the day  of vaccination.
Ensure that the participant continues to be eligible for the study , and continues to comply  
with contraception requirements detailed in Section 5.
Ensure that the participant continues to meet none of the withdrawal criteria as described 
in Section 5.2.1 and none of the temporary  delay  of vaccination or blood draw criteria as 
described in 
Section 5.2.1 .
Complete the Study  Visit/Telephone Contact AE Checklist to:
Inquire whether the participant had an y NDCMC s since the last visit.  I nquire 
whether the participant had an y of the following related to an AE since the last visit: 
hospitalizations, visits to other medical facilities, medication use, or missed day s of 
school or work.  Please refer to the SRM for additional details.
Inquire about neuroinflammatory and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis.  Please refer to the SRM for 
additional details.
Record AEs as described in the AE r eporting requirements section ( Section 8.3) and the
SoA.  Time of onset will be recorded for an y AEs that occur on the same day as 
investigational product administration.
Review AEs that 
were ongoing from the previous visit and record their end dates or 
confirm that they  are still continuing.
Record nonstud y vaccinations as described in the Concomitant T herap ysection 
(Section 6.5).
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ysection ( Section 6.5).
On the day  of vaccination, perform a urine pregnancy  test on female participants.  
Anegative pregnancy  test result is required before the participant may  receive the 
investigational product.
On the day  of and before vaccination, measure and record the participant’s oral 
temperature.
The unblinded administrator administers a single 0.5
-mL intramuscular injection of either 
MenABCWY (Groups 5 and 7) or Trumenba (Groups 6 and 8) into the upper deltoid 
muscle of th e left arm.  The time of investigational product administration will be 
recorded on the CRF.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 74Observe the participant for at least 30 minutes (or longer as per local practice) after the 
investigational product administration for any  acute reactions.  Record any AEs observed 
during the 30 -minute observation period; these AEs are defined as immediate AEs 
(Section 8.2).
Issue a participant e -diary  and provide instruction on its completion.  Ask the 
parent(s)/legal guardian or participant to complete the e -diary  from Day  1 to Day  7 after 
vaccination.  Day  1 is the day  of vaccination.
Issue a caliper, 
a measuring tape/ruler, and a digital therm ometer and provide instructions 
on their use.
Measuring tape/ruler data must be collected by the parent(s)/legal guardian for minor 
participants.  All data must be recorded in the e -diary  by the parent/legal guardian for 
minor participants.
Ask the parent( s)/legal guardian or the participant to use the caliper to measure the 
maximum diameter of redness and swelling at the left arm injection site each day  for the 
7 day s after study  vaccination and record in the e -diary  as described in Section 8.2.1.1.1.
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if the participant experiences a severe rednes s or swelling ( 20 caliper units) at the left 
arm injection site, a fever 
≥39.0°C (102.1°F), or a severe headache within 7 day s after 
vaccination, as an unscheduled visit should be arranged ( Section 8.11).
If the reaction exceeds the maximum size the caliper is able to measure ( 21 caliper 
units), the parent/legal guardian or the participant should also use the measuring 
tape/ruler to m easure the maximum diameter of redness and/or swelling at the injection 
site, and report this immediately  to the investigator. 
Ask the parent(s)/legal guardian or participant to report the maximum diameter of the 
redness and/or swelling at the injection s
ite to the investigator daily  until the reaction 
becomes ≤ 21 caliper units.
As detailed in the SRM, provide the participant with instructions and materials for 
returning the e -diary  to the investigational site after completion .
Provide the parent(s)/legal guardian or the participant with a memory  aid. Instruct the 
participant to use the memory  aid between Visits 4 and 5 to remind him or her to review 
any significant illnesses, hospitalizations, NDCMC s, or visits to a medical facility  with 
study  site personnel. The memory  aid is not a diary  for the collection of reactogenicit y.  
Please refer to the SRM for additional details.
Ask the parent(s)/legal guardian or the participant to contact the investigator immediately  
if any  significant illness or hospitaliza tion occurs.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 75Schedule an appointment for the next study  visit and confirm that it is scheduled within 
the time window per protocol.
Complete the source documents. 
Complete the CRF and update the investigational product accountability  records.
Between visi ts, review the e- diary  data online at frequent intervals. Contact the 
parent(s)/legal guardian or the participant to obtain stop dates for an y local reactions,
systemic events, or use of antipy retic medication that were ongoing on the last day  that the 
e-diary  was completed.  The stop dates should be documented in the source documents and 
the information entered into the CRF at the next study  visit of the participant.
8.10.2.4. Visit 4 (28 to 42 Days After Visit 3), Post –Vaccination 2 Telephone Contact
Visit 4 will be a telephone contact for participant sin the safet y subset (Groups 5-8).
Ensure that the participant continues to be eligible for the study , and continues to comply  
with contraception requirements detailed in Section 5.
Ensure that the participant continues to meet none of the withdrawal criteria and none of 
the temporary  delay  of blood draw criteria as described in Section 5.2.1.
Review the participant’s e -diary  data since the previous visit and follow up on any  
ongoing reactogenicity  or use of antipy retic medicatio n.
Complete the Study  Visit/Telephone Contact AE Checklist to:
Inquire whether the participant had an y NDCMC s since the last visit.  I nquire 
whether the participant had an y of the following related to an AE since the last visit: 
hospitalizations, visits to other medical facilities, medication use, or missed day s of 
school or work.  Please refer to the SRM for additional details.
Inquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple scle rosis.  Please refer to the SRM for 
additional details.
Record AEs as described in the AE 
reporting requirements section ( Section 8.3) and the
SoA.
Review AEs that were ongoing since the previous visit and record their end dates or 
confirm that they  are still continuing.
Record nonstudy  vaccinations as described in the Concomitant T
herap ysection 
(Section 6.5).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 76Record concomitant medications used to treat AE s as described in the Concomitant 
Therap ysection ( Section 6.5).
Ask the parent(s)/legal guardian or the participant to contact the in vestigator immediately  
if any  significant illness or hospitalization occurs.
Schedule a telephone contact and confirm that it is scheduled within the time window per 
protocol.
Complete the source documents.
Complete the CRFs.
8.10.2.5.
Visit 5 (168 to 196 Days After Last Vaccination), Telephone Contact
This telephone contact should occur approximately  6 months after the last study  
vaccination; this contact should be attempted for all participants who have received at 
least 1 study  vaccination, unless they  have withdr awn consent.
Contact the parent(s)/legal guardian or the participant by  telephone.
Complete the Study  Visit/Telephone Contact AE Checklist to:
Inquire about SAEs, NDCMC s, or AEs that resulted in evaluation at a medical 
facility  since the last visit.  Please refer to the SRM for additional details.
Inquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis. A checklist will be provided 
as a guide. Please refer to the SRM for addit ional details.
Report an y SAEs to the sponsor as defined in Section 8.3.
Record AEs as described in the AE 
reporting requirements sec tion ( Section 8.3) and the
SoA.
Record concomitant medications used to treat AEs as described in the Concomitant 
Therap ySection 6.5.
Review AEs that were ongoing since the previous visit and record their end dates or 
confirm th at they  are still continuing.
Complete the source documents.
Complete the CRFs.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 778.11. Unscheduled V isits
If the participant experiences a severe redness or swelling at the left arm injection site 
(20caliper units), a temperature ≥39.0°C (102.1°F), or a severe headache in the 7 day s after 
vaccination, a stud y site visit should be arranged as soon as possible to assess the extent of 
the event.  The parent(s)/legal guardian or participant contact will be documented in the CRF.
If the reaction exceeds the maximum s
ize the caliper is able to measure ( 21 caliper units,
Section 8.2.1.1.1), ensure the parent(s)/legal guardian or participant has also measured the 
maximum diameter of the redness and/or swelling at the injection site using the measuring 
tape/ruler provided.  As
k the parent(s)/legal guardian or participant to report the maximum 
diameter of the redness and/or swelling at the injection site daily  until the reaction becomes 
≤21 caliper units.  Record these measurements in the CRF.
At an unscheduled visit, the partic ipant’s oral temperature should be measured and the 
symptom that prompted the visit should be assessed by  a medicall y qualified member of the 
study  staff.  Findings will be recorded on the CRF.  If the participant experiences an y 
unsolicited AEs, these sho uld be recorded on the AE CRF.
If the unscheduled visit does not take place following participant report of fever ≥39.0°C, 
severe redness/swelling, or severe headache, the reason must be documented in the CRF 
(forexample, reaction no longer present or e -
diary entry  error).
For the purpose of assessments performed during unscheduled visits, a medically  qualified 
member of the stud y staff is a study ph ysician or a study  nurse, as applicable to the 
investigator’s local practice.
9.STATISTICAL CONSIDER
ATIONS
Methodology  for summary  and statistical anal yses of the data collected in this study  is 
outlined here and further detailed in a SAP, which will be maintained by  the sponsor.  The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
9.1.Estimands and Statistical Hypotheses
9.1.1. Estimands
The estimands corresponding to each primary , secondary ,and tertiary /exploratory  objective 
are described in the table in 
Section 3. For estimands to evaluate the immunogenicity  
objectives for noninferiority , these estimands estimate the vaccine effect in the hy pothetical 
setting where participants follow the study  schedules and protocol requirements as directed. 
This addresses the objective of estimating the maximum potential difference between 2 
groups, since the impact of noncompliance is likely  to diminish the observed difference 
between the 2 groups. The mechanism for missing data is assumed to be missing completel y 
at random ( MCAR ), and missing serology  results will not be imputed. 

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 78In the primary  safet y objective evaluations, missing e -diary  data will not be imputed. 
Missing AE dates will be imputed according t o Pfizer safet y rules .
9.1.2. Statistical Hypotheses
This study  has 2primary  objectives and 1 secondary  objective where hy pothesis testing is 
applicable.  The primary  objectives are 1) to demonstrate that the immune response induced 
by 2 doses of MenABCWY is non inferior to the immune response induced by 1 dose of 
MenACWY -CRM, for ACWY -naïve and ACWY -experienced participants separately  and 
2) to demonstrate that the immune response for MenB induced by  2 doses of MenABCWY is 
noninferior to the immune response induc ed by 2 doses of Trumenba. The hy pothesis testing 
for the secondary  objective is to demonstrate that the immune response induced by  1 dose of 
MenABCWY is noninferior to the immune response induced b y 1 dose of 
MenACWY -CRM, for ACWY -naïve and ACWY -experienced participants separately . 
Hypothesis testing for the secondary  objective will be performed only if the primary  
objectives are successful.
For all objectives evaluating noninferiority  of the immune response for MenA, MenC, 
MenW, and MenY, the definition of a seroresponder is a participant achieving at least a 
4-fold rise in hSBA titer from baseline for each ACWY test strain, at the relevant analysis 
time point.
For the ACWY noninferiority  evaluation in ACWY -
naïve participants, the immune response 
will be evaluated at 1 month following Vaccination 2 for Group 1 and at 1 month following 
Vaccination 1 for Group 2. The null hy pothesis (H 0) for each ACWY serogroup for 
noninferiority  is as follows:
H0:  π G1- πG2≤ -10%
where π G1and π G2are the percentages of participants who achieve a 4- fold rise in hSBA 
titers for MenA, MenC, MenW, and MenY for Group 1 and Group 2 ,respectivel y.  
If the lower limit of the 2- sided 95% confidence interval (CI)for the differenc e in 
seroresponders (Group 1 –Group 2) is > - 10% for all of the ACWY test strains (at 1 month 
after the second vaccination for Group 1 and at 1 month after the first vaccination for 
Group 2), the noninferiority  of the MenABCWY regimen to the MenACWY -CRM r egimen 
is declared for the ACWY -naïve participants.
For the ACWY noninferiority  evaluation in ACWY -experienced participants, the approach 
will be identical to in ACWY -naïve participants, but Group 3 will be compared to Group 4, 
instead of Group 1 compared to Group 2. The noninferiority  evaluations for both the 
ACWY -naïve and the ACWY -experienced participants are required to be successful to meet 
the first primary  objective.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 79The second primary  objective will be evaluated at 1 month following Vaccination 2 a nd the 
post–Vaccination 2 evaluable population will be used. The null hy pothesis (H 0) for 
noninferiority  for each primary  MenB test strain is as follows:
H0:  π G1+G3 -
πG2+G4 ≤ -10%
where π G1+G3 and π G2+G4 are the percentage sof 4-fold rises and composite responses for 
Groups 1 and 3 combined and for Groups 2 and 4 combined, respectivel y,at 1 month after 
the second vaccination. 
If the lower limit of the 2-sided 95% CI for the differences in 4- fold rises and composite 
respons es (Group 1+3 –Group 2+4) is > -10% for all of the primary  MenB test strains at 
1month after the second vaccination, the noninferiority  of the MenABCWY regimen to the 
Trumenba regimen is declared.
If noninferiority for both the primary objectives isdemonstrated, then an additional 
noninferiority  evaluation of the ACWY response will be performed. This evaluation will be 
a secondary  objective and will be conducted as for the primary  ACWY noninferiority  
assessment; however, the secondary  objective will be an evaluation of noninferiorit y of 
seroresponders who achieve a 4-fold rise at 1 month following V accination 1 for both groups 
evaluated (Group 1 versus Group 2 for ACWY-naïve and Group 3 versus Group 4 for 
ACWY -
experienced) .
9.1.3. Multiplicity C onsiderations
All the primary  immunogenicity  endpoints/estimands are considered coprimary  in the study . 
For the primary  immunogenicity  objectives comparing immune responses induced by  
vaccine antigens from the MenABCWY group(s) to that from the comparator group(s), 
nonin feriority  is assessed by  hypothesis tests as stated in Section 9.1.2, at a 2 -sided level of 
0.05 for each of the endpoints. The primary  immunogenicity  objectives will be met if  
noninferiority  is achieved for each endpoint. Therefore, the t ype I error rate for the 
immunogenicit y assessment is well controlled at the 0.05 level. If the primary  objectives are 
met, then testing of noninferiorit y for all the secondary endpoints related to seroresponders 
who achieve a 4
-fold rise at 1 month after Vaccination 1 w ill be done at the 0.05 level.
9.2.Sample Size Determination
9.2.1. Immunogenicity Subset (Groups 1-4)
Table 7and Table 8present the power to demonstrate that the immune response induced b y 
2 doses of MenABCWY is noninferior to the immune response induced b y 1 dose of 
MenACWY -CRM for ACWY -naïve and ACWY -experie nced participants ,respectivel y, and 
Table 9presents the power to demonstrate that the immune response induced by  2 doses of 
MenABCWY is noninferior to the immune response induced b y 2 doses of Trumenba. The 
study  is powered based on a combined (product) power across both the primary  objectives.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 80Noninferiorit y comparisons will be based on the 4 -fold rises and also composite response for 
the MenB endpoints (at 1 month following V accination 2) and seroresponders who achieve a 
4-fold respo nse for the ACWY endpoints (at 1 month after Vaccination 2 for Groups 1 and 3 
and at 1 month after Vaccination 1 for Groups 2 and 4). The lower bounds of the 
corresponding 95% CIs of the group differences will be compared to the noninferiority 
criterion ( -10%). 
With 360, 180, 540, and 270 evaluable participants in Groups 1, 2, 3, and 4 ,respectivel y,and 
the assumptions in the tables below, the power is:
above 99.9% to demonstrate noninferiorit y for the first primary  objective relating to the 
ACWY respons e in ACWY -naïve participants, 
above 99.4% to demonstrate noninferiorit y for the first primary  objective relating to the 
ACWY response in ACWY -experienced participants, and
above 91.6% for the second primary  objective relating to the MenB response. 
The co mbined power, across both primary  objectives, is above 91.0%.  Therefore, assuming 
a nonevaluable rate of 20%, 450, 225, 675, and 338 participants in Groups 1, 2, 3, and 4, 
respectivel y, will be enrolled to have sufficient evaluable participants.
Some participants may be moved from the safet y subset to the immunogenicity  subset as 
described in Section 4.1. The sponsor may  decide to proceed with less than full enrol lment if 
an assessment of power shows that it is sufficient (<91% with full enrol lment but still > 85%)
to meet the primary  objectives. This assessment will be done in a completely  blinded fashion 
before an y participants are unblinded or the immunogenicity  data areaccessed.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 81Table 7. Power Analysis for First Primary Immunogenicity Objective (ACWY - Naïve P articipants)
Criteria ACWY Test 
StrainsReference Rate 
(Group 2)aAssu med 
Difference 
(G1–G2)aNumber of 
Evaluable 
Participants 
(Group 1)Number of 
Evaluable 
Participants
(Group 2)PowerbPower to Meet 
NI for All 
Serogroups
Lower limit of 95% 
CI for the difference 
in seroresponders 
(Group 1 –Group 2) 
> -10%MenA 95.8% 0 360 180 99.96%
MenC 70% 15% 360 180 >99.99%
MenW 75.9% 15% 360 180 >99.99%
MenY 71.9% 15% 360 180 >99.99%
Power (to meet NI for all ACWY test strains) >99.93%
Abbreviations: ACWY = meningococcal groups A, C, W, and Y; G1 and G2 = Groups 1 and 2; MenA, MenC, MenW, and MenY = Neisseria meningitidis
group sA, C, W, and Y; NI = noninferiority.
a.Reference Study B1971057, ACWY -naïve participants .
b.At 0.05 alpha level (2 -sided).
Table 8.Power Analysis for First Primary Immunogenicity Objective (ACWY-E xperienced Participants) 
Criteria ACWY Test 
StrainsReference Rate 
(Group 3)aAssu med
Difference 
(G3–G4)aNumber of 
Evaluable 
Participants 
(Group 3)Number of 
Evaluable 
Participants 
(Group 4)PowerbPower to Meet NI 
for All Serogroups
Lowerlimit of 95% CI 
for the difference in 
seroresponders 
(Group 3 –Group 4) 
> -10%MenA 97% -1% 540 270 >99.99%
MenC 95.8% -1% 540 270 >99.99%
MenW 97% -2% 540 270 99.98%
MenY 94.6 -2% 540 270 99.49%
Power (to meet NI for all ACWY test strains) >99.45%
Abbreviations: ACWY = meningococcal groups A, C, W, and Y; G3 and G4 = Groups 3 and 4; MenA, MenC, MenW, and MenY = Neisseria meningitidis
groups A, C, W, and Y; NI = noninferiority.
a.Reference Study B1971057, ACWY -experienced participants.
b.At 0.05 alpha level (2 -sided).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 82Table 9. Power Analysis for Second Primary Immunogenicity Objective 
Criteria Endpoint MenB 
StrainReference Rate 
(Group s
2 +4)aAssu med
Difference 
(G1 and G3 
Combined –G2 
and G4 
Combined) Number of 
Evaluable 
Participants 
(Group s 1 + 3 
Combined)Number of 
Evaluable 
Participants 
(Group s 2 + 4 
Combined)PowerbPower to Meet 
NI for All 
Endpoints
Lower limit of 
95% CI for the 
difference in 
4-fold rises and 
composite 
responses 
(Group s 1 + 3 
combined –
Group s 2 + 4 
combined) 
>-10%hSBA titer 
fold rise
≥4from 
baselineA22 73.8% 0 900 450 98.03%
A56 95% 0 900 450 >99.99%
B24 64.5% 0 900 450 95.64%
B44 86.4% 0 900 450 99.94%
Com posite 
response72.9% 0 900 450 97.80%
Power (to meet NI for all MenB endpoints) >91.63%
Abbreviations: G1, G2, G3, and G4 = Groups 1, 2, 3, and 4; hSBA = serum bactericidal assay using human complement; Men B = Neisseria meningitidis group 
B; NI = noninferiority .
a.Reference Stud iesB1971057 and B1971012 (0 -, 6-monthschedule ) for B24 and the composite response .
b.At 0.05 alpha level (2-sided).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 83There is over 90% power to demonstrate noninferiority  for the secondary  objective for 
ACWY -naïve and - experienced participants separately , evaluating the seroresponse for 
ACWY endpoints at 1 month following vaccination for each group.
9.2.2. Additional Participants for Safety Analysis (Groups 5 -8)
The sample sizes in Groups 5, 6, 7, and 8 are not based on an y hypothesis testing but rather 
are based on havinga sufficient number of participants enrolled to sufficiently  characterize
the safet y profile of MenABCWY.  Overall, 1750 participants will be randomized to receive 
MenABCWY and 663 will be randomized to receive Trumenba + MenACWY -CRM.  
Table 10shows the probability  to detect at least 1 AE for different true incidence rates given 
that 1750 participants will receive MenABCWY.
Table 10. Probabilities of Detecting AEs at Specified Incidences
Sample Size True Incidence of AE Probability ofDetect ingat Least 1AE
1750 0.001% 1.7%
1750 0.01% 16.1%
1750 0.1% 82.6%
9.3.Populations for Analysis
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who sign the ICD .
Randomly assigned to investigational product All participants who are assigned a randomization 
number in the IRT system.
Evaluable Defined according to post–Vaccination 1 evaluable 
and post–Vaccination 2 evaluable criteria.
Modified intent -to-treat All participants who received at least 1study 
vaccination and have at least 1 valid and determinate 
MenB or MenA/C/W/Y assay result available at any 
time point from Visit 1 to Visit 4. 
Safety All randomized participants who receive at least 
1dose of the investigational product and have safety 
data reported after vaccination. Participants w ill be 
analyzed according to the vaccine they actually 
received.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 84Defined Population for Analysis Description
Post–Vaccination 1 evaluable All randomized participants who w ere eligible 
throughout Visit 2, received the investigational 
products at Visit 1 as randomized, had blood draw n 
for assay testing within the required time frames at 
Months 0 (Visit 1: before Vaccination 1) and 2 
(Visit 2: 1 month after the first vaccination: window  
28-42 days), had at least 1valid and determinate 
MenA/C/W/Y assay result at Visit 2, had received no 
prohibited vaccines or treatment through Visit 2, 
and 
had no important protocol deviations through Visit 2. 
An important protocol deviation is a protocol 
deviation that, in the opinion of the sponsor’s global 
medical monitor, w ould m aterially affect assessment 
of immunogenicity, eg, participant receipt of a 
prohibited vaccine or medication that might affect 
immu ne response or a medication error w ith suspected 
decrease in potency of the vaccine.
Post–Vaccination 2 evaluable All randomized participants who w ere eligible 
throughout Visit 4, received the investigational 
products at Visit 1 and Visit 3 as randomized, had 
blood drawn for assay testing within the required time 
frames at Months 0 (Visit 1: before Vaccination 1) 
and 7 (Visit 4: 1 month after the second vaccination: 
window  28-42 day s), had at least 1valid and 
determinate MenA/C/W/Y or MenB assay result at
Visit 4, had received no prohibited vaccines or 
treatment through Visit 4, and had no important 
protocol deviations through Visit 4. An important 
protocol deviation is a protocol deviation that, in the 
opinion of the sponsor’s global medical monitor, 
would materially affect assessment of 
immunogenicity, eg, participant receipt of a prohibited 
vaccine or medication that might affect immune 
response or a medication error w ith suspected 
decrease in potency of the vaccine.
9.4. Statistical Analyses
The SAP will be developed and finalized before database lock and will describe the 
participant populations to be included in the analy ses, and procedures for accounting for 
missing, unused, and spurious data.  This section is a summary  of the planned statistical 
analyses of the primary , secondary ,and tertiary /exploratory endpoints.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 859.4.1. Immunogenicity Analyses
Primary For each of the 4 ACWY test strains, the difference in the percentages of 
seroresponders , defined as participants achieving a 4 -fold rise from baseline, in 
Group 1 at 1 month after Vaccination 2 com pared to Group 2 at 1 month after 
Vaccination 1, and also the difference in seroresponders in Group 3 at 1 month after 
Vaccination 2 compared to Group 4 at 1 month after Vaccination 1 ,will be 
calculated.  
For each of the 4 primary MenB test strains, the differences of the 4 -fold rises and 
composite responses of Group s1 and 3 combined compared to Group s2 and 4 
combined at 1 month after V accination 2 will be calculated.  
The Miettinen and Nurminen method w ill be used to derive the CI for the difference 
in percentages between vaccine groups.   The low er limit of the CIwill be used in the 
hypothesis test for noninferiority as detailed in Section 9.1.
The analysis for the ACWY test strains is based on the post
–Vaccination 1 evaluable 
population for Group s2 and 4 and on the post –Vaccination 2 evaluable population 
for Group s1 and 3 and the analysis for the primary MenB strains is based on the 
post–Vaccination 2 evaluable population in order to provide a comparison that has the 
greatest chance of identifyin g a difference betw een the groups w ith respect to 
immunogenicity, if a meaningful difference in vaccine effect actually exists. 
Exact 2 -sided 95% CI s for the percentages (seroresponders, 4 -fold-rises and 
composite responses) will be provided using the Clo pper- Pearson method. 
Asupportive analysis will be performed based on the modified intent -to-treat (mITT) 
population. Participants will be summarized according to the vaccine group to which 
they were randomized. Missing serology data will not be imputed.
Secondary For each of the 4 ACWY test strains, the difference in the percentage of 
seroresponders, defined as participants achieving a 4 -fold rise from baseline, in 
Group 1 at 1 month after Vaccination 1 compared to Group 2 at 1 month after 
Vaccination 1, and also the differences in seroresponders between Group 3 at 1 month 
after V accination 1 and Group 4 at 1 month after Vaccination 1 ,will be calculated.  
The Miettinen and Nurminen method w ill be used to derive the CIs for the difference 
in percentages between vaccine groups. The low er limit of the CIwill be used in the 
hypothesis test for noninferiority as detailed in Section 9.1(conditional on the success 
of analysis of the prim ary objectives).
The analysis for the ACWY test strains is based on the post–V accination 1 evaluable 
population for Groups 1, 2, 3, and 4.
Percentages will be presented with 2 -sided 95% CIs using the Clopper -Pearson 
method. 
Reverse cumulative distribution functions will be provided for both MenA/C/W/Y 
strains (1 month following Vaccination 1 for Group s2 and 4 and 1 month following 
Vaccina tion 1 and Vaccination 2 for Group s1 and 3) and MenB strains (1 month 
following Vaccination 2).
Supportive analyses will be done using the mITT population. Exact 2 -sided 95% CIs 
for the percentages will be provided using the Clopper -Pearson method. Partic ipants 
will be summarized according to the vaccine group to which they were randomized. 
Missing serology data will not be imputed .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 86Tertiary/ Exploratory The follow ing analyses for the ACWY test strains arebased on the post –Vaccination 
1 evaluable population for Groups 2 and 4, and on the post –Vaccination 2 evaluable 
population for Groups 1 and 3:
The percentage of participants achieving an hSBA titer ≥1:8 for each ACWY test 
strain, at baseline and 1 month after Vaccination 1 in Groups 2 and 4, and 1 month 
after Vaccination 2 in Groups 1 and 3. 
The percentage of participants achieving hSBA titers of ≥1:8, ≥ 1:16, ≥1:32, ≥1:64, 
and ≥1:128 for each ACWY test strain, at baseline, 1 month after Vaccinati on 1 in 
Groups 2 and 4, and 1 month after Vaccination 2 in Groups 1 and 3.
hSBA GMTs for each of the ACWY test strains, at baseline, 1 month after 
Vaccination 1 in Groups 2 and 4, and 1 month after Vaccination 2 in Groups 1 and 3. 
The follow ing analyses f or the ACWY test strains are based on the post –Vaccination 
1 evaluable population for all g roups:
The percentage of participants achieving an hSBA titer ≥1:8 for each ACWY test 
strain, at baseline and 1 month after Vaccination 1 in Groups 1 through 4.
The percentage of participants achieving hSBA titers of ≥1:8, ≥ 1:16, ≥1:32, 
≥1:64, and ≥1:128 for each ACWY test strain, at baseline and 1 month after 
Vaccination 1 in Groups 1 through 4.
hSBA GMTs for each of the ACWY test strains, at baseline and 1 month aft er 
Vaccination 1 in Groups 1 through 4.
The follow ing analyses are for the prim ary MenB test strains:
The percentage of participants achieving an hSBA titer ≥LLOQ (1:16 for A22 and 
1:8 for A56, B24, and B44) for each primary MenB test strain in Groups 1 +3 
combined and Groups 2 +4 combined, at baseline and 1 month after Vaccination 2 ,
will be summarized using the post –Vaccination 2 evaluable population.
The percentage of participants w ith hSBA titers ≥1:4, ≥ 1:8, ≥1:16, ≥1:32, ≥1:64, and 
≥1:128 for each of the 4 primary MenB test strains in Groups 1 +3 combined and 
Groups 2 +4 combined, at baseline and 1 month after Vaccination 2 ,will be 
summarized using the post –Vaccination 2 evaluable population. MenB hSBA GMTs 
for each of the 4 primar y MenB test strains in Groups 1 +3 combined and Groups 2 +
4 combined, at baseline and 1 month after Vaccination 2 ,will be summarized using 
the post –Vaccination 2 evaluable population.
The percentage of participants achieving an hSBA titer ≥LLOQ for each secondary 
MenB test strain in Groups 1 + 3 combined, at baseline and 1 month after 
Vaccination 2, will be summarized using the post –Vaccination 2 evaluable 
population.
The percentage of participants w ith hSBA titers ≥1:4, ≥ 1:8, ≥1:16, ≥1:32, ≥1:64, and 
≥1:128 for each of the secondary MenB test strains in Groups 1 + 3 combined, at 
baseline and 1 month after Vaccination 2, will be summarized using the 
post–Vaccination 2 evaluable population. 
hSBA GMTs for each of the secondary MenB test strains in Groups 1 + 3 combined, 
at baseline and 1 month after Vaccination 2, will be summarized using the 
post–Vaccination 2 evaluable population.
Percentages will be presented with 2 -sided 95% CIs using the Clopper -Pearson 
method. Geometric means and their 2 -sided CIs will be derived by calculating means 
and CIs on the natural log scale based on the t -distribution, and then exponentiating 
the results. Titers below  LLOQ w ill be set to 0.5 × LLOQ for analysis.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 87Supportive analyses will be done using the mITT population. Participants w ill be 
summarized according to the vaccine group to which they were randomized. Missing 
serology data will not be imputed .  
9.4.2. Safety Analyses
All safet y anal yses will be performed on the safet y population. Separate safety  populations 
will be defined for each vaccination visit and follow -up phase , Vaccination 1, Vaccination 2, 
and follow -up phase ,and will be detailed in the SAP.
Endpoint Statistical Analysis Methods
Primary The proportion of participants reporting local reactions at the investigational product 
administration site and systemic events within the 7 -day period after each vaccination 
will be descriptively summarized by MenABCWY and Trumenba combined groups 
(ie, Gr oups 1, 3, 5, and 7 combined compared to Groups 2, 4, 6, and 8 combined).  
Two(2)-sided 95% CIs based on the Clopper -Pearson method w ill be presented with 
the proportions.  Severities of local reactions and systemic events reported after each 
vaccination will also be descriptively summarized by the same MenABCWY and 
Trumenba combined groups.  Local reactions will be summarized only for the left 
arm, which is the MenABCWY or Trumenba injection site.
The proportion of participants reporting the use of antipy retic m edication for Days 1 
to 7 will be compiled for MenABCWY and Trumenba combined groups after each 
vaccination.
All AEs and SAEs will be categorized according to the latest version of the Medical 
Dictionary for Regulatory Activities ( MedDRA ).  An MAE is defined as a nonserious 
AE that results in an evaluation at a medical facility.  A nNDCMC is defined as a 
disease or medical condition not previously identified that is expected to be persistent 
or otherw ise long -lasting in its effects.  AEs, SAEs, MAEs,and NDCMC s will be 
summarized by vaccine group.
A 3-tier approach w ill be used to summarize AEs. Under this approach AEs are 
classified into 1 of 3 tiers: (1) Tier 1 events are prespecified events of clinical
importance; (2) Tier 2 events are those that are not Tier 1 but are considered 
“relatively common”; a MedDRA preferred term is defined as a Tier 2 event if there 
are at least 4 participants in at least 1(combined) vaccine group reporting the event; 
and (3) Tier 3 events are those that are neither Tier 1 nor Tier 2 events. For both 
Tier 1 and Tier 2 events, the 95% CIs for the difference in percentage of participants 
reporting the events between MenABCWY and Trumenba combined groups will be 
calculated using the Miettinen and Nurminen method. There is no Tier 1 event 
identified for MenABCWY at this stage. Descriptive summary statistics (counts and 
percentages and associated Clopper -Pearson 95% CIs) w ill be provided for Tier 3 
events for MenABCWY and Trumenba combined groups.
Participants will be analyzed according to the vaccine they actually received. 
Missing e -diary data will not be imputed; missing AE dates will be handled according 
to the Pfizer safety rules.
Detailed analyses for each safety endpoint will be addressed in the SAP.
Secondary Not applicable .
Tertiary/ Exploratory Not applicable .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 889.5.Interim Analyses
No interim anal ysis is planned for the stud y. Onl y 1analysis will be performed at the 
completion of the study . 
9.5.1. Data Monitoring Committee 
This study  will use an E-DMC.
An independent statistician will provide unblinded safet y reports to the E -DMC for review.  
Safety  data will be reviewed by  the E -DMC throughout the study , and no adjustments to the 
type I error for the noninferiorit y assessments will be made for these per iodic safet y reviews.
The E-DMC will be responsible for ongoing monitoring of the safet y of participants in the 
study  according to the charter.  The recommendations made by  the E -DMC to alter the 
conduct of the stud y will be forwarded to Pfizer for final d ecision.  Pfizer will forward such 
decisions, which may  include summaries of aggregate anal yses of endpoint events and of 
safet y data that are not endpoints, to regulatory authorities, as appropriate.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 8910. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS 
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from interna tional guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines;
Applicable International Council for Harmonisation (I CH) GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, IB, and other relevant documents 
(eg, advertisements) must be reviewed and approved by  the sponsor and submitted to an 
IRB/EC by  the investigator and reviewed and appr oved by  the IRB/EC before the study  is 
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or more 
frequentl y in accordance with the requirements, policies, and procedures established by 
the IRB/EC;
Notify ing the IR B/EC of SAEs or other significant safet y findings as required by IRB/EC 
procedures;
Providing oversight of the conduct of the stud y at the site and adherence to requirements 
of 21 CFR, I CH guidelines, the I RB/EC, European regulation 536/2014 for clinical 
studies (if applicable), and all other applicable local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any  area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately. 
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 9010.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities.  I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her parent(s)/legal guardian and answer all questions regarding the stud y.
Participants must be informed that their participation is voluntary .  Participants or their 
parent(s)/legal guardian will be required t o sign a statement of informed consent that meets 
the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance 
Portability  and Accountability  Act (HIPAA) requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant or his or her parent(s)/legal guardian 
is fully  informed about the nature and objectives of the study, the sharing of data related to 
the study , and possible risks associated with participation, including the risks associated with 
the processing of the participant’s personal data. 
The participant or his or her parent(s)/legal guardian must be informed that his/her personal 
study -related data will be used by  the sponsor in accordance with local data protection law.  
The level of disclosure must also be explained to the participant.
The participant or his or her parent(s)/legal guardian must be informed that his/her medical 
records may  be examined by  Clinical Qualit y Assurance auditors or other authorized 
personnel appointed b y the sponsor, b y appropriate I RB/EC members, and by  inspectors 
from regulatory  authorities.
The investigator further must ensure that each study  participant or his or her parent(s)/legal 
guardian is fully  informed about his or her right to acce ss and correct his or her personal data 
and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtained.  
The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
A cop y of the ICD(s) mu st be provided to the participant or the parent(s)/legal guardian .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 91A study -specific assent form will be provided to pediatric participants as required by  local 
regulations.  I t is to be understood as the adolescent's will to participate in a trial after 
having received age -appropriate information and is sometimes also referred to as 
"knowing agreement."  If the study  includes minor 
participants who reach the age of majority  
during the stud y, as recognized under local law, they must reconsent as adults to re main in 
the study .  If the enrollment of emancipated minors is permitted by  the study  age criteria, the 
IRB/EC, and local law, they  must provide documentation of legal status to give consent 
without the permission of a parent or legal guardian.
10.1.4. Data Protec tion
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal dat a can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required b y law.
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code.
Any participant records or data sets that are transferred to the spons or will contain the 
numerical code; participant names will not be transferred.  All other identifiable data 
transferred to the sponsor will be identified by  this single, participant -specific code.  The 
study  site will maintain a confidential list of partic ipants who participated in the study , 
linking each participant’s numerical code to his or her actual identity .  In case of data 
transfer, the sponsor will protect the confidentiality of participants’ personal data consistent 
with the clinical study  agreeme nt and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Tri als 
Database (EudraCT) /Clinical Trial Information Sy stem (CTIS) , and/or www.pfizer.com, and 
other public registries in accordance with applicable local laws/regulations.  I n addition, 
Pfizer reports study  results outside of the requirements of local laws/r egulations pursuant to 
its standard operating procedures (SOPs).
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 92www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted.  These results are 
submitted for posting in accordance with the format and timelines set forth by  US law.
EudraCT /CTI S
Pfizer posts clinical trial results on EudraCT/CTI S for Pfizer sponsored interventional studies 
in accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts CSR synopses and plain language study  results summaries on www.pfizer.com
forPfizer -sponsored interventional studies at the same time the corresponding study  results 
are posted to www.clinicaltrials.gov. CSR synopses will have personally  identifiable 
information anon ymized.
Documents within marketing applications
Pfizer complies with applicable local laws /regula tionsto publish clinical documents included 
in marketing applications. Clinical documents include summary  document sand CSRs 
including the protocol and protocol amendments, sample CRFs and SAPs. Clinical 
documents will have personally identifiable infor mation anony mized.
Data Sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class.  Pf izer will make data from these trials available
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses.  Research teams must include a biostatistician.  Data will not 
be provided to applicants with significant conflicts of interest, including indivi duals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data).  The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 93The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are passwor d protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.  Th is 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk- based initiatives in operations and quality  
such as risk management and mitigation strategies and anal ytical risk- based monitoring), 
methods, responsibilities, and requirements, including handling of noncomp liance issues and 
monitoring techniques (central, remote, or on -site monitoring), are provided in the
monitoring plan.
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected ; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period.  No records may  be destroy ed during 
the retention period without the written approval of th e sponsor.  No records may  be 
transferred to another location or part y without written notification to the sponsor.  The 
investigator must ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 94The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to t he study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator si te and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copies of the inspection findings to the sponsor or its agent.  Before res ponse 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.  Source documents are filed at the investigator site.
Data reported on the CRF or entered in the electronic CRF (eCRF) that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained.  The investigator may need to request previous medical records or transfer 
records, depending on the study .  Also, current medical records must be available.
Definition of what constitutes source da ta can be found in the S RM.
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor.  Study  sites will be closed upon 
study  completion.  A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y
-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the contract 
research organization (CRO) if requested to do so by  the responsible IRB/EC or if such 
termination is required to protect the health of study participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of t he investigator to comply  with the protocol, the requirements of the I RB/EC 
or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development.
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 9510.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 y ear after end of the study  
(or study  termination), whichever comes first. 
The investigator agrees to r efer to the primary  publication in any  subsequent publications 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission.  This allows the sponsor to protect proprietary  information and to 
provide comm ents and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer 
intervention -related information necessary  for the appropriate scientific presentation or 
understandin g of the study results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors .
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites.  I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.  I n this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with International Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located in the investigator site file. 
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participants are provided with a contact card.  The contact card 
contains, at a minimum, protocol and investigational product identifiers, participant 
numbers, contact information for the investigator site, and contact details for a contact 
center in the event that the investigator site staff cannot be reached to provide advice on a 
medical question or problem originating from another healthcare professional not involved 
inthe participant’s participation in the study .  The contact number can also be used b y 
investigator staff if they  are seeking advice on medical questions or problems; however, 
itshould be used only  in the event that the established communication pathway s between 
theinvestigator site and the study  team are not available.  I t is therefore intended to augment, 
but not replace, the established communication pathway s between the investigator site and 
the study  team for advice on medical questions or problems that may  arise during the study .  

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 96The contact number is not intended for use by the participant directl y, and if a participant 
calls that number, he or she will be directed back to the investigator site.
10.2. Appendix 2: Clinical Laboratory Tests
Not a pplicable .
10.3.
Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the stu dy intervention.
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new  or exacerbated) temporally associated w ith the use of study 
intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety 
assessments (eg, electrocardiogram [ECG] , radiological scans, vital sign measurements), including those 
that worsen from baseline, cons idered clinically significant in the medical and scientific judgment of the 
investigator (ie, not related to progression of underlying disease).
Exacerbation of a chronic or intermittent preexisting condition including either an increase in frequency 
and/o r intensity of the condition.
New  conditions detected or diagnosed after study intervention administration even though it may have 
been present before the start of the study.
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a 
concomitant medication.  Overdose per se w ill not be reported as an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self -harming in tent.  Such overdoses should be reported regardless 
of sequelae.
The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as an AE 
or SAE if they fulfill the definition of an AE or SAE.  Also, “lack of efficacy” or “fa ilure of expected 
pharmacological action” constitutes an AE or SAE.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 97Events NOT Meeting the AE Definition
Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying disease, unless judged by the investigator to be more severe than 
expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder 
being studied, unless more severe than expected for th e participant’s condition.
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure 
is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or convenience admission 
to a hospital ).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the 
start of the study that do not worsen.
10.3.2. Definition of an NDCMC
An NDCMC is defined as a disease or medical condition, not previously  identified, th at is 
expected to be persistent or is otherwise long -lasting in its effects.
10.3.3. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward m edical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the participant was at 
risk of death at the time of the event.  It does not refer to an event that hypothetically might have caused 
death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually involving at least an 
overnight stay) at the hospital or emergency ward for observation and/or treatment that w ould not have been 
appropriate in the physician’s office or outpatient setting.  Complications that occur during hospitalization 
are AEs.  If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious.  
When in doubt as to whether “hospitalization” occurred or was necessary, the AE sh ould be considered 
serious.
Hospitalization for elective treatment of a preexisting condition that did not w orsen from baseline is not 
considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability to conduct normal life functions.
This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained 
ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 98An SAE is defined as any untoward m edical occurrence that, at any dose:
e.Is a congenital anom aly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE reporting i s appropriate in 
other situations such as important medical events that may not be immediately life -threatening or result 
in death or hospitalization but may jeopardize the participant or may require medical or surgical 
intervention to prevent one of the o ther outcomes listed in the above definition.  These events should 
usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in an emergency 
room  or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization, or development of drug dependency or drug abuse.
10.3.4. Recording/Reporting and Follow -up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below  summarizes the requirements for recording adverse events on the CRF and for reporting 
serious adverse events on the Vaccine SAE Reporting Form to Pfizer Safety.  These requirements are 
delineated for 3 types of events: (1) SAEs; (2) nonserious AEs; and (3) exposure to the investigational product 
under st udy during pregnancy or breastfeeding, and occupational exposure. 
It should be noted that the Vaccine SAE Reporting Form for reporting of SAE information is not the same as 
the AE page of the CRF .  When the same data are collected, the forms must be completed in a consistent 
manner.  AEs should be recorded using concise medical terminology and the same AE term should be used on 
both the CRF and the Vaccine SAE Reporting Form for reporting of SAE i nformation.
Safety Event Recorded on the CRF Reported on the Vaccine SAE 
Reporting Form to Pfizer Safety 
Within 24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the investigational 
product under study during 
pregnancy or breastfeeding, 
and occupational exposureNone All (and exposure during 
pregnancy [EDP] supplemental 
form for EDP)  
When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospital progress notes, laboratory reports, and diagnostic reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s medical records to Pfizer 
Safety in lieu of com pletion of the Vaccine SAE Reporting Form /AE/SAE CRF page.
There may be instances when copies of medical records for certain cases are requested by Pfizer Safety.  
In this case, all participant identifiers, with the exception of the participant numb er, w ill be redacted on 
the copies of the medical records before submission to Pfizer Safety.
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other 
clinical information.  Whenever possible, the diagnosis (not the individual signs/symptoms) w ill be 
documented as the AE/SAE.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 99Assessment of Intensity
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described in the 
definition of an SAE, NOT when it is rated as severe .
GRADE If required on the AE page of the CRF, the investigator w ill use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity of the AE. For purposes of 
consistency, these intensity grades are defined as follows:
1 MILD Does not interfere with participant's usual function.
2 MODERATE Interferes to some extent with participant's usual function.
3 SEVERE Interferes significantly with participant's usual function.
Assessment of Causality
The investigator is obligated to assess the relationship between study intervention and each occurrence of 
each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to 
suggest a causal relationship, rather than a relationship cannot be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as w ell as 
the temporal relationship of the event to study interventio n administration will be considered and 
investigated.
The investigator will also consult the IB and/or product information, for marketed products, in his/her 
assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.
There may be situations in which an SAE has occurred and the investigator has minimal information to 
include in the initial report to the sponsor.  How ever, it is very im portant that the investigator always 
make an assessment of causality for every event before the initial transmission of the SAE data to 
the sponsor.
The investigator may change his/her opinion of causality in light of follow -up information and send an 
SAE follow -up report w ith the updated causality assessment.
The causality assessment is one of the criteria used when determining regulatory reporting requirements.
If the investigator does not know  whether or not the investigational product caused the event, then the 
event will be handled as “related to investigational product” for reporting purposes, as defined by the 
sponsor.  In addition, if the investigator determines that an SAE is associated w ith study procedures, the 
investigator must record this causal relationship in the s ource documents and CRF, and report such an 
assessment in the dedicated section of the Vaccine SAE Reporting Form and in accordance w ith the SAE 
reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or 
evaluations as medically indicated or as requested by the sponsor to elucidate the nature and/or causality 
of the AE or SAE as fully as possible.  This may include additional laboratory tests or investigation s, 
histopathological examinations, or consultation with other healthcare professionals.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 100Follow -up of AEs and SAEs
If a participant dies during participation in the study or during a recognized follow -up period, the 
investigator will provide Pfizer Safety with a copy of any postmort em findings including histopathology.  
New  or updated information will be recorded in the originally completed CRF.
The investigator will submit any updated SAE data to the sponsor w ithin 24 hours of receipt of the 
information.
10.3.5. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary mechanism for reporting an SAE to Pfizer Safety will be the electronic data collection tool.
If the electronic system is unavailable, then the site will use the paper SAE data collection tool ( see next 
section) in order to report the event within 24 hours.
The site w ill enter the SAE data into the electronic system as soon as the data become available.
After the study is completed at a given site, the electronic data collection tool w ill be taken off -line to 
prevent the entry of ne w data or changes to existing data.
If a site receives a report of a new SAE from a study participant or receives updated data on a previously 
reported SAE after the electronic data collection tool has been taken off -line, then the site can report this 
information on a paper SAE form (see next section) or to Pfizer Safety by telephone.
SAE Reporting to Pfizer Safety via Vaccine SAE Reporting Form
Facsimile transmission of the Vaccine SAE Reporting For mis the preferred method to transmit this 
information to Pfizer Safety.
In circumstances when the facsimile is not w orking, notification by telephone is acceptable with a copy 
of the Vaccine SAE Reporting Form sent by overnight mail or courier service.
Initial notification via telephone does not replace the need for the investigator to complete and sign the 
Vaccine SAE Reporting Form pages within the designated reporting time frames.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 10110.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Inform ation
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28 day safter the last dose of stud y intervention:
Refrain from donating sperm.
PLUSeither :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent. 
OR
Must agree to use a male condom when engaging in any  activity that allows for passage 
of ejaculate to another person.
In addition to male condom use, a highl y effective method of contraception is 
recommended in WOCBP partners of male participants (refer to the list of high ly 
effective methods below in Section 10.4.4).
10.4.2. Female P
articipant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using an acceptable contraceptive method as described below during 
the intervention period (for a minimum of 28 day s after the last dose of study  
intervention).  The investigator should evaluate the effectiveness of the contraceptive 
method in relationship to the first dose of stud y intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetecte d 
pregnancy . 
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 102If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menst rual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenarchal.  
2.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview.  The method of documentation should be recorded in the participant’s medical 
record for the stud y.
3.Postmenopausal female:
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause . 
A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormone replacement therap y (HRT). 
Females on HRT and whose menopausal status is in doubt will be required to use 
one of the nonestrogen hormonal highl y effective contraception methods if they 
wish to continue their HRT during the stud y.  Otherwise, they must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.
10.4.4. Contraception Methods
1.Implant able progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device (IUD).
3.Intrauterine hormone -releasing s ystem (IUS).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 1034.Bilateral tubal occlusion.
5.Vasectomized partner:
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed.  If not, an additional highly  effective method 
of contraception should be used.  The spermatogenes is cycle is approximately  
90days.
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
oral;
intravaginal;
transdermal;
injectable.
7.Progestogen -only hormone contraception associated with inhibitio n of ovulation:
oral;
injectable.
8.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.  The reliabi lity of sexual abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifest yle of the 
participant.
9.Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary  mode of action.
10. Male or female condom with or without spermicide.
11. Cervical cap, diaphragm, or sponge with spermicide.
12. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 104Collection of Pregnancy Information
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact with 
a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the tim e of conception and/or is exposed during 
his partner’s pregnancy .
If a participant or participant’s partner becomes or is found to be pregnant during the 
participant’s treatment with the investigational product, the investigator must report this 
information to Pfizer Safety  on the Vaccine SAE Reporting Form and an EDP su pplemental 
form, regardless of whether an SAE has occurred.   In addition, the investigator must submit 
information regarding environmental exposure to a Pfizer product in a pregnant woman 
(eg, a participant reports that she is pregnant and has been expose d to a cy totoxic product by  
inhalation or spillage) to Pfizer Safety using the EDP supplemental form.  This must be done 
irrespective of whether an AE has occurred and within 24 hours of awareness of the 
exposure.  The information submitted should include the anticipated date of delivery  
(see below for information related to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will fol low the pregnancy  
until completion (or until pregnancy termination) and notify Pfizer Safet y of the outcome as 
afollow -up to the initial EDP supplemental form.  I n the case of a live birth, the structural 
integrit y of the neonate can be assessed at the ti me of birth.  In the event of a termination, 
thereason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless
preprocedure test findings ar e conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 105Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard to 
causality , as SAEs.  In addition, infant deaths after 1 month should be reported as SAEs 
when the investigator assesses the infant death as related or possibly  related to exposure 
to the investigational product. 
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg , follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must docum ent in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 10610.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up Assessments 
Potential Cases of Drug- Induced Liver Injury
Human s exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as drug -induced 
liver injury  (DILI).  Participants who experience a transaminase elevation above 3 times the 
upper limit of normal (× ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safet y monitoring procedure in this 
study .  However, should an investigator deem it necessary  to assess LFTs because a 
participant presents with clinical signs/s ymptoms, such LFT results should be managed and 
followed as described below.
In the majority  of DILI cases, elevations in aspartate aminotr ansferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values wi ll be elevated within the same laboratory  
sample).  In rare instances, by  the time TBili elevations are detected, AST/AL T values might 
have decreased.  This occurrence is still regarded as a potential DILI.  
Therefore, abnormal elevations in either AST OR ALT in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases 
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been e xcluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions.  Participants who present 
with the following laboratory  abnormalities should be evaluated furthe r as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 × ULN AND a TBili value >2 ×ULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 ×ULN or not 
available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, a s needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT values 
>2times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is smaller).

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 107Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches >3 ×ULN 
(whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; an y case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y wit hin 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment.
In addition to repeating measurements of AST and AL T and TBili for suspected cases of 
Hy’s law, additional la boratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time (PT)/international 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevatio n defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 10810.6. Appendix 6: Medical Device Incidents: Definition and Procedures for Recording,
Evaluating, Follow -up, and Reporting
Definitions of a Medical Device Incident
The detection and documentation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the stud y (see Section 6.1.2) for the list of sponsor 
medical devices).
Medical Device Incident Definition
A medical device incident is any malfunction or deterioration in the characteristics and/or performance of 
a device as well as any inadequacy in the label ing or the instructions for use which, directly or indirectly, 
might lead to or might have led to the death of a participant/user/other person or to a serious deterioration 
in his/her state of health.
Not all incidents lead to death or serious deterioratio n in health.  The nonoccurrence of such a result might 
have been due to other fortunate circumstances or to the intervention of healthcare personnel.
It is sufficient that:
An incident associated with a device happened.
AND
The incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health.
A serious deterioration in state of health can include an y of the following:
Life-threatening illness;
Permanent impairment of body  function or permanent damage to body  structure;
Condition necessitating medical or surgical intervention to prevent one of the above;
Fetal distress, fetal death, or an y congenital abnormality  or birth defects.
Examples of Incidents
A participant, user, caregiver, or healthcare professional is injured as a result of a medical device failure 
or its misuse.
A participant’s study intervention is interrupted or compromised by a medical device failure.
A misdiagnosis due to medical device failure leads to inappropriate treatment.
A partici pant’s health deteriorates due to medical device failure.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 109Documenting Medical Device Incidents
Medical Device Incident Documentation
Any medical device incident occurring during the study will be documented in the participant’s medical 
records, in accordance w ith the investigator’s normal clinical practice, and on the appropriate form of the 
CRF .
For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE CRF page will be 
completed as described in Appendix 3 .
The CRF will be completed as thoroughly as possible and signed by the investigator before transmittal to 
the sponsor or designee.
It is very important that the unblinded site staff provides his/her assessment of causality (relationship to 
the m edical device provided by the sponsor) at the time of the initial AE or SAE report and describes any 
corrective or remedial actions taken to prevent recurrence of the incident.
A remedial action is any action other than routine maintenance or servicing of a medical device where 
such action is necessary to prevent recurrence of an incident.  This includes any amendment to the device 
design to prevent recurrence.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 11010.7. Appendix 7: Abbreviations
The following is a list of abbreviations that may  be used in the pro tocol.
Abbreviation Term
ACIP Advisory  Committee on Immunization Practices
ACWY meningococcal group A, C, W, and Y 
AE adverse event
AlPO 4 aluminum phosphate
ALT alanine aminotransferase
AST aspartate aminotransferase
bivalent rL P2086 bivalent recombinant lipoprotein 2086 vaccine (Trumenba)
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention
CDP clinical development program
CFR Code of Federal Regulations
CI confidence interval
COVID -19 coronavirus disease 2019
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CRF case report form
CRM cross -reactive material
CRO contract research organization
CSR clinical study  report
CT clinical trial
DILI drug-induced liver injury
DTaP -Hib diphtheria, tetanus, and acellular pertussis and 
Haemophilus influenzae type b vaccine
dTaP-IPV diphtheria, tetanus, and acellular pertussis and inactivated 
poliomy elitis virus vaccine
DU dispensable unit
EC ethics committ ee
ECG electrocardiogram
eCRF electronic case report form
e-diary electronic diary
E-DMC external data monitoring committee 
EDP exposure during pregnancy
EMA European Medicines Agency
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration (United States)
fHBP factor H binding protein
FIH first-in-human
FSH follicle -stimulating hormone

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 111Abbreviation Term
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMT geometric mean titer
GSK GlaxoSmithKline
HBV -IPV hepatitis B virus and inactivated poliomy elitis virus vaccine
HIPAA Health Insurance Portability  and Accountability  Act
HPV4 human papillomavirus vaccine
HRT hormone replacement therap y
hSBA serum bactericidal assay using human complement
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IMD invasive meningococcal disease
IMP investigational medicinal product
IND investigational new drug application
INR international normalized ratio
IP manual investigational product manual
IRB institutional review board
IRT interactive response technology
IUD intrauterine device
IUS intrauterine hormone -releasing s ystem
IVRS interactive voice response sy stem
IWRS interactive Web -based response sy stem 
LFT liver function test
LLOQ lower limit of quantitation
LOD limit of detection
MAE medically  attended adverse event
MCAR missing completel y at random
MCV4- Tdap quadrivalent meningococcal polysaccharide conjugate and 
diphtheria, tetanus, and acellular pertussis vaccine
MedDRA Medical Dictionary  for Regulatory  Activities
MenA Neisseria meningitidis group A
MenABCWY Neisseria meningitidis group A, B, C, W, and Y vaccine
MenACWY -CRM meningococcal groups A, C, Y, and W- 135 oligosaccharide 
diphtheria conjugate vaccine (Menveo)
MenACWY -TT meningococcal poly saccharide groups A, C, W-135, and Y tetanus 
toxoid conjugate vaccine (Nimenrix)
MenB Neisseria meningitidis group B
MenC Neisseria meningitidis group C
MenCYW -135 meningococcal group C, Y, and W -135
MenW Neisseria meningitidis group W

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 112Abbreviation Term
MenY Neisseria meningitidis group Y
mITT modified intent -to-treat
NDCMC newly  diagnosed chronic medical condition
NIMP noninvestigational medicinal product
PACL protocol administrative change letter
PCD primary  completion date
PFS prefilled s yringe
POC proof of concept
PRP-OMP polyribos ylribitol phosphate oligosaccharide of 
Haemophilus influenzae type b conjugated to outer membrane 
protein
PT prothrombin time
rSBA serum bactericidal assay  using rabbit complement
SAE serious adverse event
SAP statistical analy sis plan
SoA schedule of activities
SOP standard operating procedure
SRM study  reference manual
SRSD single reference safet y document
SUSAR suspected unexpected serious adverse reaction
TBili total bilirubin
ULN upper limit of normal
US United States
USPI US package insert
WOCBP woman/women of childbearing potential

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 11311.REFERENCES
1. Wang B, Clarke M, Thomas N, et al. The clinical burden and predictors of sequelae 
following invasive meningococcal disease in Australian children. Pediatr Infect Dis J 
2014;33(3) :316-8.
2. Harrison LH, Pelton SI, Wilder -Smith A, et al. The Global Meningococcal I nitiative: 
recommendations for reducing the global burden of meningococcal disease. Vaccine 
2011;29(8) :3363 -71.
3. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal 
disease: recommendations of the Advisory  Committee on I mmunization Practices 
(ACI P). MMWR Recomm Rep 2013;62 (2):1-28.
4. Centers for Disease Control and Prevention. Enhanced meningococcal disease 
surveillance 
report, 2017. Available from: 
https://www.cdc.gov/meningococcal/downloads/NCI RD-EMS- Report -2017.pdf . 
Accessed: 20 Nov 2019.
5. Walker TY, Elam- Evans LD, Yankey  D, et al. National, regional, s tate, and selected 
local area vaccination coverage among adolescents aged 13-17 years - United States, 
2018. MMWR Morb Mortal Wkly  Rep 2019;68(33):718 -23.
6. Centers for Disease Control and Prevention. Enhanced m eningococcal disease 
surveillance 
report, 2016. Available from: 
https://www.cdc.gov/meningococcal/downloads/NCI RD-EMS- Report.pdf . 
Accessed: 20 Nov 2019.
7. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease 
epidemiology  in the United States, 1998-2007: implications for prevention of 
meningococcal disease. Clin I nfect Dis 2010;50(2):184-91.
8. Mandal S, Wu HM, MacNeil JR, et al. Prolonged university outbreak of meningococcal 
disease associated with a se rogroup B strain rarel y seen in the United States. Clin I nfect 
Dis 2013;57(3):344
-8.
9. European Centre for Disease Prevention and Control.  Surveillance report. Surveillance 
of invasive bacterial diseases in Europe, 2007. Stockholm, Sweden: ECDC; 20 10. 
Available from:
https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/10101
1_SUR_Surveillance_of_invasive_bacterial_diseases_in_Europe_2007.pdf . 
Accessed :
10 March 2015.

PF-06886992 ( Neisseria meningitidis Group A, B, C, W, and Y Vaccine [MenABCWY])
Protocol C3511001
Final Protocol Amendment 2, 13June 2022
PFIZER CONFIDENTIAL
Page 11410. European Centre for Disease Prevention and Control. Survei llance report. Annual 
epidemiological report: reporting on 2011 surveillance data and 2012 epidemic 
intelligence data. Stockholm, Sweden: ECDC; 2013. Available from: 
http://ecdc.europa.eu/en/publications/_lay outs/forms/Publication_DispForm.aspx?L ist=
4f55a d51-4aed - 4d32- b960 -af70113dbb90&ID=989. Accessed : 11 March 2016.
11. National Foundation for Infectious Diseases. Addressing the challenges of serogroup B 
meningococcal disease outbreaks on campuses: a report b y the National Foundation for 
Infectious Diseases . May 2014. Available from : 
http://www.nfid.org/publications/reports/meningococcal-b- outbreaks.pdf .
Accessed: 
14 Dec 2014.
12. Wendling P. Campus meningitis outbreaks tamed but can our approach last? 28 Feb 
2014. Available from : 
http://www.clinicalneurology news.com/index.php?id=9843&cHash=071010&tx_ttnews
[tt_news]=239545.  
Accessed: 14 Dec 2014.
13. Centers for Disease Control and Prevention. Meningococcal vaccine recommendations. 
Available from: https://www.cdc.gov/vaccines/vpd/mening/hcp/recommendations.html. 
Last reviewed : 26 Jul 2019. Accessed: 27 Nov 2019. 
14. US Food and Drug Administration. Guidance for industry : toxicity  grading scale for 
healthy  adult and adolescent volunteers e nrolled in preventive vaccine clinical trials.  
Rockville, MD: Center for Biologics Evaluation and Research; September 2007.

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH		





	
'RFXPHQW 7LWOH !"#$%&"'%()#!' #**"#+ ( )+
*%!""' %*'#','-'#* +%*%'-!"%$$.!#/!%%'-#,$+0-%!*'- '%%!'1	'#23- #,/
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
PPD
PPD